

Morphometric evidence for neuronal and glial prefrontal
depression—See accompanying Editorial, in this issue

Biological Psychiatry

45, 1085-1098

DOI: 10.1016/s0006-3223(99)00041-4

Citation Report

#	ARTICLE	IF	CITATIONS
1	Neuroanatomic Substrates of Late-Life Mental Disorders. Journal of Geriatric Psychiatry and Neurology, 1999, 12, 95-106.	2.3	17
2	Prefrontal Corticalâ€”Amygdalar Metabolism in Major Depression. Annals of the New York Academy of Sciences, 1999, 877, 614-637.	3.8	486
3	Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?. Biological Psychiatry, 1999, 46, 929-940.	1.3	297
4	Neural plasticity to stress and antidepressant treatment. Biological Psychiatry, 1999, 46, 1181-1191.	1.3	601
5	Pet imaging of serotonin 1A receptor binding in depression. Biological Psychiatry, 1999, 46, 1375-1387.	1.3	598
7	Molecular Mechanisms Underlying Mood Stabilization in Manic-Depressive Illness: The Phenotype Challenge. American Journal of Psychiatry, 1999, 156, 1506-1514.	7.2	83
8	Chapter 9 Biological aspects of depression. Principles of Medical Biology, 2000, 14, 179-205.	0.1	0
9	Chronic Antidepressant Treatment Increases Neurogenesis in Adult Rat Hippocampus. Journal of Neuroscience, 2000, 20, 9104-9110.	3.6	2,822
11	Prefrontal cortical projections to the striatum in macaque monkeys: Evidence for an organization related to prefrontal networks. Journal of Comparative Neurology, 2000, 425, 447-470.	1.6	327
12	More than one-half of a decade of experience with venlafaxine dual serotonin-norepinephrine reuptake inhibitor. Depression and Anxiety, 2000, 12, 1-1.	4.1	0
13	Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety, 2000, 12, 2-19.	4.1	746
14	Evidence for progression of brain structural abnormalities in schizophrenia: beyond the neurodevelopmental model. Australian and New Zealand Journal of Psychiatry, 2000, 34, S113-S126.	2.3	31
15	The mitochondrial hypothesis of bipolar disorder. Bipolar Disorders, 2000, 2, 145-147.	1.9	9
16	Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs. Molecular Psychiatry, 2000, 5, 425-432.	7.9	168
17	Neuroplasticity and cellular resilience in mood disorders. Molecular Psychiatry, 2000, 5, 578-593.	7.9	313
18	Psychiatric Comorbidity in Chronic Epilepsy: Identification, Consequences, and Treatment of Major Depression. Epilepsia, 2000, 41, S31-S41.	5.1	310
19	The Corticosteroid Receptor Hypothesis of Depression. Neuropsychopharmacology, 2000, 23, 477-501.	5.4	1,859
20	Increased Temporal Cortex ER Stress Proteins in Depressed Subjects Who Died by Suicide. Neuropsychopharmacology, 2000, 22, 327-332.	5.4	77

#	ARTICLE	IF	CITATIONS
21	An in-vivo magnetic resonance imaging study of the olfactory bulbectomized rat model of depression. Brain Research, 2000, 879, 193-199.	2.2	64
22	Electroconvulsive seizures modulate levels of thyrotropin releasing hormone and related peptides in rat hypothalamus, cingulate and lateral cerebellum. Brain Research, 2000, 884, 174-183.	2.2	24
23	The neurobiology of stress: from serendipity to clinical relevance11Published on the World Wide Web on 22 November 2000.. Brain Research, 2000, 886, 172-189.	2.2	1,521
24	cAMP Response Element-Mediated Gene Transcription Is Upregulated by Chronic Antidepressant Treatment. Journal of Neuroscience, 2000, 20, 4030-4036.	3.6	496
25	Pharmacotherapy of Early-Onset Depression. Child and Adolescent Psychiatric Clinics of North America, 2000, 9, 135-157.	1.9	27
26	Evidence for Progression of Brain Structural Abnormalities in Schizophrenia: Beyond the Neurodevelopmental Model. Australian and New Zealand Journal of Psychiatry, 2000, 34, A113-A126.	2.3	20
27	Evidence for Progression of Brain Structural Abnormalities in Schizophrenia: Beyond the Neurodevelopmental Model. Australian and New Zealand Journal of Psychiatry, 2000, 34, S113-S126.	2.3	32
28	Molecular Abnormalities in Brains of Depressed Patients. Neuroscientist, 2000, 6, 401-410.	3.5	0
29	Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biological Psychiatry, 2000, 47, 475-481.	1.3	278
30	Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia. Biological Psychiatry, 2000, 47, 80-83.	1.3	60
31	The serotonin transporter in the midbrain of suicide victims with major depression. Biological Psychiatry, 2000, 47, 1015-1024.	1.3	73
32	Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex—a possible mechanism of neuroprotection in major depression?. Neuroscience, 2000, 100, 681-684.	2.3	102
33	Serotonin type-1A receptor imaging in depression. Nuclear Medicine and Biology, 2000, 27, 499-507.	0.6	182
34	Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders. Archives of General Psychiatry, 2000, 57, 925.	12.3	1,664
35	The Organization of Networks within the Orbital and Medial Prefrontal Cortex of Rats, Monkeys and Humans. Cerebral Cortex, 2000, 10, 206-219.	2.9	2,246
36	Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Progress in Brain Research, 2000, 126, 413-431.	1.4	565
37	Histopathology of the prefrontal cortex in major depression: what does it tell us about dysfunctional monoaminergic circuits?. Progress in Brain Research, 2000, 126, 397-412.	1.4	80
38	The Anatomical Connections of the Macaque Monkey Orbitofrontal Cortex. A Review. Cerebral Cortex, 2000, 10, 220-242.	2.9	804

#	ARTICLE	IF	CITATIONS
39	Neuroimaging in Pursuit of Neurobiology: Strengths, Limitations, and the Quest for New Paradigms in Depression and Mood. American Journal of Geriatric Psychiatry, 2000, 8, 284-288.	1.2	3
40	Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biological Psychiatry, 2000, 48, 1-8.	1.3	379
41	Signaling: cellular insights into the pathophysiology of bipolar disorder. Biological Psychiatry, 2000, 48, 518-530.	1.3	195
42	Neuronal plasticity and survival in mood disorders. Biological Psychiatry, 2000, 48, 732-739.	1.3	584
43	Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biological Psychiatry, 2000, 48, 1053-1061.	1.3	138
44	Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biological Psychiatry, 2000, 48, 766-777.	1.3	750
45	Effects of adverse experiences for brain structure and function. Biological Psychiatry, 2000, 48, 721-731.	1.3	562
46	Neuropathology of bipolar disorder. Biological Psychiatry, 2000, 48, 486-504.	1.3	127
47	Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biological Psychiatry, 2000, 48, 740-754.	1.3	332
48	3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biological Psychiatry, 2000, 48, 791-800.	1.3	413
49	Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biological Psychiatry, 2000, 48, 861-873.	1.3	300
50	Neuroimaging studies of mood disorders. Biological Psychiatry, 2000, 48, 813-829.	1.3	1,154
51	Reduction of orbital frontal cortex volume in geriatric depression. Biological Psychiatry, 2000, 48, 971-975.	1.3	203
52	Medial orbital frontal lesions in late-onset depression. Biological Psychiatry, 2001, 49, 803-806.	1.3	149
53	Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biological Psychiatry, 2001, 49, 753-762.	1.3	298
54	Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biological Psychiatry, 2001, 49, 741-752.	1.3	521
55	Are child-, adolescent-, and adult-onset depression one and the same disorder?. Biological Psychiatry, 2001, 49, 980-1001.	1.3	228
56	The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biological Psychiatry, 2001, 49, 1023-1039.	1.3	2,337

#	ARTICLE	IF	CITATIONS
57	Performance feedback deficit in geriatric depression. <i>Biological Psychiatry</i> , 2001, 50, 358-363.	1.3	67
58	Immunohistochemical Localization of Phosphorylated Glial Fibrillary Acidic Protein in the Prefrontal Cortex and Hippocampus from Patients with Schizophrenia, Bipolar Disorder, and Depression. <i>Brain, Behavior, and Immunity</i> , 2001, 15, 388-400.	4.1	161
59	Validating Cortical Surface Analysis of Medial Prefrontal Cortex. <i>NeuroImage</i> , 2001, 14, 1058-1069.	4.2	30
60	Interferons: potential roles in affect. <i>Medical Hypotheses</i> , 2001, 56, 558-566.	1.5	27
61	Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. <i>Brain Research Bulletin</i> , 2001, 55, 651-659.	3.0	118
62	Glial cell abnormalities in major psychiatric disorders: the evidence and implications. <i>Brain Research Bulletin</i> , 2001, 55, 585-595.	3.0	418
63	Electron microscopy of oligodendroglia in severe mental illness. <i>Brain Research Bulletin</i> , 2001, 55, 597-610.	3.0	450
64	Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. <i>Brain Research Bulletin</i> , 2001, 55, 569-578.	3.0	248
65	The role of the brain reward system in depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001, 25, 781-823.	4.8	212
66	Stress, memory, and the hippocampus: can't live with it, can't live without it. <i>Behavioural Brain Research</i> , 2001, 127, 137-158.	2.2	450
67	Tianeptine and its enantiomers: effects on spatial memory in rats with medial septum lesions. <i>Neuropharmacology</i> , 2001, 41, 272-281.	4.1	24
68	CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. <i>Medical Clinics of North America</i> , 2001, 85, 559-577.	2.5	30
69	Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers. <i>British Journal of Psychiatry</i> , 2001, 178, s107-s119.	2.8	121
70	Characterization of Extracellular Dopamine Clearance in the Medial Prefrontal Cortex: Role of Monoamine Uptake and Monoamine Oxidase Inhibition. <i>Journal of Neuroscience</i> , 2001, 21, 35-44.	3.6	110
71	Genetic Analysis of Brain Imaging Abnormalities. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2001, 10, 241-258.	1.9	3
72	Family, Genetic, and Imaging Studies of Early-Onset Depression. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2001, 10, 375-390.	1.9	16
73	The place of lithium salts in psychiatric practice 50 years on. <i>Current Opinion in Psychiatry</i> , 2001, 14, 57-63.	6.3	8
74	ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment. <i>Journal of ECT</i> , 2001, 17, 27-32.	0.6	52

#	ARTICLE	IF	CITATIONS
75	Influence of SAME on the modifications of brain polyamine levels in an animal model of depression. <i>NeuroReport</i> , 2001, 12, 3939-3942.	1.2	43
76	Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. <i>Psychopharmacology</i> , 2001, 158, 100-106.	3.1	334
77	Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. <i>Journal of Neurochemistry</i> , 2001, 77, 916-928.	3.9	299
78	Commentary on PTSD discussion. <i>Hippocampus</i> , 2001, 11, 82-84.	1.9	32
79	The cellular neurobiology of depression. <i>Nature Medicine</i> , 2001, 7, 541-547.	30.7	1,050
80	Changed Concentrations of Tachykinins and Neuropeptide Y in Brain of a Rat Model of Depression Lithium Treatment Normalizes Tachykinins. <i>Neuropsychopharmacology</i> , 2001, 24, 183-191.	5.4	46
81	Stem Cells in Neurodevelopment and Plasticity. <i>Neuropsychopharmacology</i> , 2001, 25, 805-815.	5.4	47
82	Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. <i>Current Opinion in Neurobiology</i> , 2001, 11, 240-249.	4.2	1,004
83	Stress, sex, hippocampal plasticity: relevance to psychiatric disorders. <i>Clinical Neuroscience Research</i> , 2001, 1, 19-34.	0.8	27
84	Depression, antidepressants, and the shrinking hippocampus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 12320-12322.	7.1	279
85	Depression – emerging insights from neurobiology. <i>British Medical Bulletin</i> , 2001, 57, 61-79.	6.9	181
86	Psychiatry and the microscope - the application of cellular brain quantitation to characterize psychiatric disorders. <i>International Review of Psychiatry</i> , 2001, 13, 7-11.	2.8	0
87	Reduced Glial Cell Density and Neuronal Size in the Anterior Cingulate Cortex in Major Depressive Disorder. <i>Archives of General Psychiatry</i> , 2001, 58, 545.	12.3	701
88	The Mood Stabilizer Valproic Acid Activates Mitogen-activated Protein Kinases and Promotes Neurite Growth. <i>Journal of Biological Chemistry</i> , 2001, 276, 31674-31683.	3.4	300
89	New Concepts for Prevention and Treatment of Late-Life Depression. <i>American Journal of Psychiatry</i> , 2001, 158, 835-838.	7.2	43
90	Cyclic AMP response element-binding protein and depression. <i>Expert Review of Neurotherapeutics</i> , 2002, 2, 347-354.	2.8	13
91	Unmasking Disease-Specific Cerebral Blood Flow Abnormalities: Mood Challenge in Patients With Remitted Unipolar Depression. <i>American Journal of Psychiatry</i> , 2002, 159, 1830-1840.	7.2	325
92	Vascular basis of late-onset depressive disorder. <i>British Journal of Psychiatry</i> , 2002, 180, 157-160.	2.8	158

#	ARTICLE	IF	CITATIONS
93	Brain Imaging in Mood Disorders. , 0, , 815-828.		2
94	Executive Control Function. Journal of Neuropsychiatry and Clinical Neurosciences, 2002, 14, 377-405.	1.8	455
95	Glial fibrillary acidic protein in late life major depressive disorder: an immunocytochemical study. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 556-560.	1.9	68
96	The neuropathology of primary mood disorder. Brain, 2002, 125, 1428-1449.	7.6	289
97	Prefrontal Cortical Volume in Childhood-Onset Major Depression. Archives of General Psychiatry, 2002, 59, 173.	12.3	113
98	Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry, 2002, 7, S71-S80.	7.9	513
99	Stress, Metaplasticity, and Antidepressants. Current Molecular Medicine, 2002, 2, 629-638.	1.3	107
100	Synaptic plasticity and mood disorders. Molecular Psychiatry, 2002, 7, S29-S34.	7.9	310
101	c- fos mRNA Induction in Acute and Chronic Audiogenic Stress: Possible Role of the Orbitofrontal Cortex in Habituation. Stress, 2002, 5, 121-130.	1.8	85
102	Reduced Neuronal Size and Glial Cell Density in Area 9 of the Dorsolateral Prefrontal Cortex in Subjects with Major Depressive Disorder. Cerebral Cortex, 2002, 12, 386-394.	2.9	527
103	Regulation of the Injury-Immune Response in the Central Nervous System. , 2002, , 773-V.		2
104	Anatomical MRI findings in mood and anxiety disorders. Epidemiologia E Psichiatria Sociale, 2002, 11, 88-99.	0.9	89
105	Structural Changes in the Brain in Depression and Relationship to Symptom Recurrence. CNS Spectrums, 2002, 7, 129-139.	1.2	74
106	White Matter Injury, Neural Connectivity and the Pathophysiology of Psychiatric Disorders. Developmental Neuroscience, 2002, 24, 255-261.	2.0	44
107	Probing Brain Reward System Function in Major Depressive Disorder. Archives of General Psychiatry, 2002, 59, 409.	12.3	214
108	Neurokinin-1 receptors are decreased in major depressive disorder. NeuroReport, 2002, 13, 1223-1227.	1.2	57
109	Circumscribed numerical deficit of dorsal raphe neurons in mood disorders. Psychological Medicine, 2002, 32, 93-103.	4.5	100
110	Chronic, treatment-resistant depression and right fronto-striatal atrophy. British Journal of Psychiatry, 2002, 180, 434-440.	2.8	114

#	ARTICLE	IF	CITATIONS
111	The Establishment of a Brain Bank for the Study of Late-life Depression: A Feasibility Study of Factors Facilitating Consent. <i>CNS Spectrums</i> , 2002, 7, 816-821.	1.2	4
112	Stress and the progression of the developmental hypothesis of schizophrenia. <i>British Journal of Psychiatry</i> , 2002, 181, 363-365.	2.8	90
113	Decreased Levels of N-Acetylaspartate in Dorsolateral Prefrontal Cortex in a Case of Intractable Severe Sympathetically Mediated Chronic Pain (Complex Regional Pain Syndrome, Type I). <i>Brain and Cognition</i> , 2002, 49, 102-113.	1.8	55
114	Volumetric reduction in left subgenual prefrontal cortex in early onset depression. <i>Biological Psychiatry</i> , 2002, 51, 342-344.	1.3	337
115	Reduced volume of orbitofrontal cortex in major depression. <i>Biological Psychiatry</i> , 2002, 51, 273-279.	1.3	480
116	Enlargement of the amygdala in patients with a first episode of major depression. <i>Biological Psychiatry</i> , 2002, 51, 708-714.	1.3	285
117	Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. <i>Biological Psychiatry</i> , 2002, 51, 775-787.	1.3	332
118	Proton magnetic resonance spectroscopic imaging in pediatric major depression. <i>Biological Psychiatry</i> , 2002, 52, 86-92.	1.3	103
119	Smaller frontal lobe white matter volumes in depressed adolescents. <i>Biological Psychiatry</i> , 2002, 52, 413-417.	1.3	109
120	Low glial numbers in the amygdala in major depressive disorder. <i>Biological Psychiatry</i> , 2002, 52, 404-412.	1.3	462
121	Glia pathology in the prefrontal cortex in alcohol dependence with and without depressive symptoms. <i>Biological Psychiatry</i> , 2002, 52, 1121-1133.	1.3	137
122	Neural and behavioral substrates of mood and mood regulation. <i>Biological Psychiatry</i> , 2002, 52, 478-502.	1.3	355
123	Comorbidity of late life depression: an opportunity for research on mechanisms and treatment. <i>Biological Psychiatry</i> , 2002, 52, 543-558.	1.3	206
124	Increased duration of illness is associated with reduced volume in right medial temporal/anterior cingulate grey matter in patients with chronic schizophrenia. <i>Schizophrenia Research</i> , 2002, 57, 43-49.	2.0	80
125	Non-reduction in hippocampal volume is associated with higher risk of psychosis. <i>Schizophrenia Research</i> , 2002, 58, 145-158.	2.0	153
126	Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. <i>Schizophrenia Research</i> , 2002, 57, 127-138.	2.0	192
127	Structural plasticity and tianeptine: cellular and molecular targets. <i>European Psychiatry</i> , 2002, 17, 318s-330s.	0.2	90
128	Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. <i>European Neuropsychopharmacology</i> , 2002, 12, 527-544.	0.7	516

#	ARTICLE	IF	CITATIONS
129	Morphological Brain Changes in Depression. CNS Drugs, 2002, 16, 361-372.	5.9	61
130	The role of CREB and other transcription factors in the pharmacotherapy and etiology of depression. Annals of Medicine, 2002, 34, 348-356.	3.8	51
131	Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience, 2002, 114, 807-815.	2.3	87
132	Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Research, 2002, 109, 143-148.	3.3	1,061
133	Sex differences in the effects of neonatal handling on the animal's response to stress and the vulnerability for depressive behaviour. Behavioural Brain Research, 2002, 129, 131-139.	2.2	99
134	Experience-dependent asymmetric variation in primate prefrontal morphology. Behavioural Brain Research, 2002, 136, 51-59.	2.2	65
135	The neurobiology and neuroendocrinology of stress. Psychiatric Clinics of North America, 2002, 25, 469-494.	1.3	128
136	Frontostriatal and Limbic Dysfunction in Late-Life Depression. American Journal of Geriatric Psychiatry, 2002, 10, 687-695.	1.2	124
137	Etiology and genetics of early-onset mood disorders. Child and Adolescent Psychiatric Clinics of North America, 2002, 11, 499-518.	1.9	23
138	Clinical Presentation of the "Depression-Executive Dysfunction Syndrome" of Late Life. American Journal of Geriatric Psychiatry, 2002, 10, 98-106.	1.2	103
139	The Neuroendocrinology of Cognitive Disorders. , 0, , 273-282.		1
140	Molecular Mechanisms of Action of Mood Stabilizers in Bipolar Disorder. , 2002, 21, 112-136.		1
141	Cell adhesion molecule expression in the dorsolateral prefrontal cortex and anterior cingulate cortex in major depression in the elderly. British Journal of Psychiatry, 2002, 181, 129-134.	2.8	41
142	Cell adhesion molecule expression in the dorsolateral prefrontal cortex and anterior cingulate cortex in major depression in the elderly. British Journal of Psychiatry, 2002, 181, 129-134.	2.8	61
143	Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?. Journal of Affective Disorders, 2002, 69, 1-14.	4.1	86
144	Autonomous Neurobiological Pathways to Late-Life Major Depressive Disorder Clinical and Pathophysiological Implications. Neuropsychopharmacology, 2002, 26, 229-236.	5.4	44
145	The Human Brain Revisited Opportunities and Challenges in Postmortem Studies of Psychiatric Disorders. Neuropsychopharmacology, 2002, 26, 143-154.	5.4	174
146	Anatomical MRI Study of Subgenual Prefrontal Cortex in Bipolar and Unipolar Subjects. Neuropsychopharmacology, 2002, 27, 792-799.	5.4	146

#	ARTICLE	IF	CITATIONS
147	R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus An in vivo Microdialysis and Receptor Binding Study. Neuropsychopharmacology, 2002, 27, 949-959.	5.4	138
148	Neuropsychiatric applications of DTI – a review. NMR in Biomedicine, 2002, 15, 587-593.	2.8	215
149	Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology, 2002, 160, 353-361.	3.1	278
150	When cells become depressed: focus on neural stem cells in novel treatment strategies against depression. Journal of Neural Transmission, 2002, 109, 947-962.	2.8	35
151	Cell pathology in bipolar disorder. Bipolar Disorders, 2002, 4, 105-116.	1.9	169
152	Volumetric brain imaging findings in mood disorders. Bipolar Disorders, 2002, 4, 89-104.	1.9	197
153	Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disorders, 2002, 4, 166-182.	1.9	110
154	Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder?. Bipolar Disorders, 2002, 4, 80-88.	1.9	178
155	Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disorders, 2002, 4, 129-136.	1.9	218
156	Antidepressants and neuroplasticity. Bipolar Disorders, 2002, 4, 183-194.	1.9	436
157	Regulation of adult hippocampal neurogenesis – implications for novel theories of major depression. Bipolar Disorders, 2002, 4, 17-33.	1.9	205
158	Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. Journal of Neurochemistry, 2002, 80, 589-597.	3.9	299
159	Enhancement of Hippocampal Neurogenesis by Lithium. Journal of Neurochemistry, 2000, 75, 1729-1734.	3.9	527
160	Norepinephrine alters the expression of genes involved in neuronal sprouting and differentiation: relevance for major depression and antidepressant mechanisms. Journal of Neurochemistry, 2002, 83, 1054-1064.	3.9	63
161	Functional expression of the norepinephrine transporter in cultured rat astrocytes. Journal of Neurochemistry, 2002, 84, 136-144.	3.9	72
162	Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Molecular Psychiatry, 2002, 7, 604-608.	7.9	67
163	Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Molecular Psychiatry, 2002, 7, 985-994.	7.9	359
164	Up-regulation of 5-HT _{2B} receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochemical Research, 2002, 27, 113-120.	3.3	109

#	ARTICLE	IF	CITATIONS
165	Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. <i>Cellular and Molecular Neurobiology</i> , 2002, 22, 25-33.	3.3	235
166	The Electroconvulsive Therapy Controversy: Evidence and Ethics. <i>Neuropsychology Review</i> , 2003, 13, 199-219.	4.9	51
167	Glutamate and Depression. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 250-272.	3.8	375
168	Regulation of Cellular Plasticity Cascades in the Pathophysiology and Treatment of Mood Disorders. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 273-291.	3.8	165
169	Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 292-308.	3.8	145
170	NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. <i>Psychopharmacology</i> , 2003, 169, 215-233.	3.1	477
171	Association between dorsolateral prefrontal N-acetyl aspartate and depression in chronic back pain: an in vivo proton magnetic resonance spectroscopy study. <i>Journal of Neural Transmission</i> , 2003, 110, 287-312.	2.8	67
172	Differential expression of α_2 -adrenoceptor vs. imidazoline binding sites in postmortem orbitofrontal cortex and amygdala of depressed subjects. <i>Journal of Psychiatric Research</i> , 2003, 37, 399-409.	3.1	10
173	Comparison of prefrontal cell pathology between depression and alcohol dependence. <i>Journal of Psychiatric Research</i> , 2003, 37, 411-420.	3.1	58
174	Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. <i>Journal of Psychiatric Research</i> , 2003, 37, 357-373.	3.1	328
175	The distribution and morphology of prefrontal cortex pyramidal neurons identified using anti-neurofilament antibodies SMI32, N200 and FNP7. Normative data and a comparison in subjects with schizophrenia, bipolar disorder or major depression. <i>Journal of Psychiatric Research</i> , 2003, 37, 487-499.	3.1	57
176	Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states. <i>Neuroscience and Biobehavioral Reviews</i> , 2003, 27, 233-246.	6.1	393
177	Early and Late Neurodevelopmental Disturbances in Schizophrenia and Their Functional Consequences. <i>Australian and New Zealand Journal of Psychiatry</i> , 2003, 37, 399-406.	2.3	161
178	Molecular correlates of impaired prefrontal plasticity in response to chronic stress. <i>Journal of Neurochemistry</i> , 2003, 85, 1312-1323.	3.9	94
179	Attenuated 5-HT _{1A} receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase. <i>Journal of Neurochemistry</i> , 2003, 87, 182-194.	3.9	141
180	Molecular targets of lithium action. <i>Acta Neuropsychiatrica</i> , 2003, 15, 316-340.	2.1	29
181	Metabolic changes after repetitive transcranial magnetic stimulation (rTMS) of the left prefrontal cortex: a sham-controlled proton magnetic resonance spectroscopy (1H MRS) study of healthy brain. <i>European Journal of Neuroscience</i> , 2003, 17, 2462-2468.	2.6	138
182	Experience effects on brain development: possible contributions to psychopathology. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2003, 44, 33-63.	5.2	147

#	ARTICLE	IF	CITATIONS
183	Neuroimaging and neurocircuitry models pertaining to the neurosurgical treatment of psychiatric disorders. <i>Neurosurgery Clinics of North America</i> , 2003, 14, 213-223.	1.7	160
184	Mapping brain size and cortical gray matter changes in elderly depression. <i>Biological Psychiatry</i> , 2003, , .	1.3	1
185	MRNA expression patterns and distribution of white matter neurons in dorsolateral prefrontal cortex of depressed patients differ from those in schizophrenia patients. <i>Biological Psychiatry</i> , 2003, 53, 39-47.	1.3	53
186	Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. <i>Biological Psychiatry</i> , 2003, 53, 338-344.	1.3	238
187	Smaller orbital frontal cortex volumes associated with functional disability in depressed elders. <i>Biological Psychiatry</i> , 2003, 53, 144-149.	1.3	80
188	Subcortical lesion severity and orbitofrontal cortex volume in geriatric depression. <i>Biological Psychiatry</i> , 2003, 54, 529-533.	1.3	72
189	Quantitative spectral analysis of EEG in psychiatry revisited: drawing signs out of numbers in a clinical setting. <i>Clinical Neurophysiology</i> , 2003, 114, 2294-2306.	1.5	83
190	The concept of allostasis in biology and biomedicine. <i>Hormones and Behavior</i> , 2003, 43, 2-15.	2.1	2,524
191	Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. <i>Neuropharmacology</i> , 2003, 45, 935-944.	4.1	109
192	Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. <i>Biological Psychiatry</i> , 2003, 53, 1086-1098.	1.3	229
193	Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression. <i>Biological Psychiatry</i> , 2003, 53, 707-742.	1.3	461
194	Mood disorders and allostatic load. <i>Biological Psychiatry</i> , 2003, 54, 200-207.	1.3	913
195	Neuroimaging studies of mood disorder effects on the brain. <i>Biological Psychiatry</i> , 2003, 54, 338-352.	1.3	566
196	Proton magnetic resonance spectroscopic imaging of the brain in childhood autism. <i>Biological Psychiatry</i> , 2003, 54, 1355-1366.	1.3	102
197	Lithium stimulates progenitor proliferation in cultured brain neurons. <i>Neuroscience</i> , 2003, 117, 55-61.	2.3	93
198	Does increased platelet release of A β peptide contribute to brain abnormalities in individuals with depression?. <i>Medical Hypotheses</i> , 2003, 60, 640-643.	1.5	26
199	Brain plasticity and pathology in psychiatric disease: sites of action for potential therapy. <i>Current Opinion in Pharmacology</i> , 2003, 3, 33-40.	3.5	43
200	Depression: What We can Learn from Postmortem Studies. <i>Neuroscientist</i> , 2003, 9, 273-284.	3.5	98

#	ARTICLE	IF	CITATIONS
201	Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. Expert Opinion on Investigational Drugs, 2003, 12, 65-86.	4.1	27
202	Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 313-317.	7.1	204
203	Proton Magnetic Resonance Spectroscopy in First Episode Psychosis and Ultra High-Risk Individuals. Schizophrenia Bulletin, 2003, 29, 831-843.	4.3	113
204	Abnormal Expression and Functional Characteristics of Cyclic Adenosine Monophosphate Response Element Binding Protein in Postmortem Brain of Suicide Subjects. Archives of General Psychiatry, 2003, 60, 273.	12.3	167
205	Cellular Pathology in the Dorsolateral Prefrontal Cortex Distinguishes Schizophrenia from Bipolar Disorder. Current Molecular Medicine, 2003, 3, 427-436.	1.3	60
206	Cognition in mania and depression. Psychological Medicine, 2003, 33, 959-967.	4.5	98
207	Depression with late onset is associated with right frontal lobe atrophy. Psychological Medicine, 2003, 33, 675-681.	4.5	76
208	Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychological Medicine, 2003, 33, 1277-1284.	4.5	227
209	Dual Monoamine Modulation for Improved Treatment of Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2003, 23, 78-86.	1.4	114
210	Up-regulation of the D1 Dopamine Receptor Interacting Protein, Calcyon, in Patients With Schizophrenia. Archives of General Psychiatry, 2003, 60, 311.	12.3	71
211	Glial loss in mood disorders and schizophrenia. Advances in Molecular and Cell Biology, 2003, 31, 1049-1057.	0.1	0
212	The Biological, Social, and Psychological Relationship Between Depression and Chronic Pain. Cranio - Journal of Craniomandibular Practice, 2003, 21, 286-294.	1.4	32
213	Gene Profile of Electroconvulsive Seizures: Induction of Neurotrophic and Angiogenic Factors. Journal of Neuroscience, 2003, 23, 10841-10851.	3.6	342
214	Psychopharmakotherapie: pharmakologische Grundlagen. , 2003, , 513-564.		1
215	The Neurobiology of Child and Adolescent Depression: Current Knowledge and Future Directions. , 2003, , 461-490.		2
216	Psychosocial Stressors as Predisposing Factors to Affective Illness and PTSD: Potential Neurobiological Mechanisms and Theoretical Implications. , 2003, , 491-525.		5
217	The neuropathology of mood disorders. , 2003, , 291-307.		1
218	Social separation models of depression. , 2003, , 338-372.		0

#	ARTICLE	IF	CITATIONS
219	Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects. <i>Journal of Neuroscience</i> , 2003, 23, 349-357.	3.6	720
220	Status of neurosurgery for mental disorder in Scotland. <i>British Journal of Psychiatry</i> , 2003, 182, 404-411.	2.8	53
221	Regional Brain Metabolic Correlates of β -Methylparatyrosine-Induced Depressive Symptoms. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 3125.	7.4	111
223	Regulation of Neurogenesis and Angiogenesis in Depression. <i>Current Neurovascular Research</i> , 2004, 1, 261-267.	1.1	71
224	Neuropathologic Correlates of Late-Onset Major Depression. <i>Neuropsychopharmacology</i> , 2004, 29, 2242-2250.	5.4	96
225	Neuropathological Study of the Dorsal Raphe Nuclei in Late-Life Depression and Alzheimer's Disease With and Without Depression. <i>American Journal of Psychiatry</i> , 2004, 161, 1096-1102.	7.2	100
226	Subtype-Specific Alterations of β -Aminobutyric Acid and Glutamate in Patients With Major Depression. <i>Archives of General Psychiatry</i> , 2004, 61, 705.	12.3	704
227	Gene Expression Profiling of Depression and Suicide in Human Prefrontal Cortex. <i>Neuropsychopharmacology</i> , 2004, 29, 351-361.	5.4	105
228	Structural MRI Changes of the Brain in Depression. <i>Clinical EEG and Neuroscience</i> , 2004, 35, 46-52.	1.7	36
229	Effects of Electroconvulsive Therapy on Frontal White Matter in Late-Life Depression: A Diffusion Tensor Imaging Study. <i>Neuropsychobiology</i> , 2004, 50, 48-53.	1.9	82
230	Lower Hippocampal Volume in Patients Suffering From Depression: A Meta-Analysis. <i>American Journal of Psychiatry</i> , 2004, 161, 598-607.	7.2	978
231	Acute Stress-induced Changes in Hippocampal/Prefrontal Circuits in Rats: Effects of Antidepressants. <i>Cerebral Cortex</i> , 2004, 14, 224-229.	2.9	270
232	Age-Dependent Reductions in the Level of Glial Fibrillary Acidic Protein in the Prefrontal Cortex in Major Depression. <i>Neuropsychopharmacology</i> , 2004, 29, 2088-2096.	5.4	230
233	Anterior Cingulate, Cingulate Gyrus, and Orbitofrontal Abnormalities in Elderly Depressed Patients: An MRI-Based Parcellation of the Prefrontal Cortex. <i>American Journal of Psychiatry</i> , 2004, 161, 99-108.	7.2	344
234	ATF2, A Member of the CREB/ATF Family of Transcription Factors, in Chronic Stress and Consequent to Antidepressant Treatment: Animal Models and Human Post-Mortem Brains. <i>Neuropsychopharmacology</i> , 2004, 29, 589-597.	5.4	20
235	Depression and bulbar involvement in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2004, 5, 245-249.	1.2	35
236	Volumetric Analysis of the Prefrontal Cortex, Amygdala, and Hippocampus in Major Depression. <i>Neuropsychopharmacology</i> , 2004, 29, 952-959.	5.4	324
237	Low nNOS protein in the locus coeruleus in major depression. <i>Journal of Neurochemistry</i> , 2004, 91, 1057-1066.	3.9	74

#	ARTICLE	IF	CITATIONS
238	Changes in brain metabolism associated with remission in unipolar major depression. <i>Acta Psychiatrica Scandinavica</i> , 2004, 110, 184-194.	4.5	108
239	Different levels of β -synuclein mRNA in the cerebral cortex of dominant, neutral and submissive rats selected in the competition test. <i>Genes, Brain and Behavior</i> , 2004, 4, 60-64.	2.2	18
240	In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. <i>Molecular Psychiatry</i> , 2004, 9, 326-357.	7.9	553
241	Hippocampal neurochemical pathology in patients at first episode of affective psychosis: a proton magnetic resonance spectroscopic imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2004, 131, 95-105.	1.8	52
242	Biophysical changes in normal-appearing white matter and subcortical nuclei in late-life major depression detected using magnetization transfer. <i>Psychiatry Research - Neuroimaging</i> , 2004, 130, 131-140.	1.8	90
243	Deficiency of theory of mind in patients with remitted mood disorder. <i>Journal of Affective Disorders</i> , 2004, 82, 403-9.	4.1	175
244	Do epilepsy and psychiatric disorders share common pathogenic mechanisms? A look at depression and epilepsy. <i>Clinical Neuroscience Research</i> , 2004, 4, 31-37.	0.8	10
245	Neurotrophins as Mediators of Drug Effects on Mood, Addiction, and Neuroprotection. <i>Molecular Neurobiology</i> , 2004, 29, 289-302.	4.0	84
246	Role of Neurotrophic Factors in the Etiology and Treatment of Mood Disorders. <i>NeuroMolecular Medicine</i> , 2004, 5, 011-026.	3.4	463
247	Adolescence: Vulnerable Period for Stress-Induced Prefrontal Cortical Function? Introduction to Part IV. <i>Annals of the New York Academy of Sciences</i> , 2004, 1021, 143-147.	3.8	57
248	Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: Importance for psychiatric diseases. <i>Neurotoxicity Research</i> , 2004, 6, 233-244.	2.7	123
249	Effect of stress on prefrontal cortex function. <i>Neurotoxicity Research</i> , 2004, 6, 73-78.	2.7	64
250	Principal component and volume of interest analyses in depressed patients imaged by ^{99m}Tc -HMPAO SPET: a methodological comparison. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 995-1004.	6.4	10
251	Longitudinal Association of Initiation/Perseveration and Severity of Geriatric Depression. <i>American Journal of Geriatric Psychiatry</i> , 2004, 12, 50-56.	1.2	52
253	Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. <i>Schizophrenia Research</i> , 2004, 67, 269-275.	2.0	599
254	Decreased hippocampal 5-HT _{2A} receptor binding in major depressive disorder: in vivo measurement with [^{18}F]altanserin positron emission tomography. <i>Biological Psychiatry</i> , 2004, 55, 217-224.	1.3	148
255	Anatomic evaluation of the orbitofrontal cortex in major depressive disorder. <i>Biological Psychiatry</i> , 2004, 55, 353-358.	1.3	216
256	Mapping brain size and cortical gray matter changes in elderly depression. <i>Biological Psychiatry</i> , 2004, 55, 382-389.	1.3	82

#	ARTICLE	IF	CITATIONS
257	Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biological Psychiatry, 2004, 55, 563-569.	1.3	320
258	Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biological Psychiatry, 2004, 55, 1095-1102.	1.3	99
259	Depression: a case of neuronal life and death?. Biological Psychiatry, 2004, 56, 140-145.	1.3	532
260	Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biological Psychiatry, 2004, 56, 570-580.	1.3	347
261	Hippocampal changes and white matter lesions in early-onset depression. Biological Psychiatry, 2004, 56, 825-831.	1.3	81
262	Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophrenia Research, 2004, 69, 317-323.	2.0	115
263	Is major depression a neurologic disorder with psychiatric symptoms?. Epilepsy and Behavior, 2004, 5, 636-644.	1.7	61
264	Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology, 2004, 46, 232-242.	4.1	60
265	Chronic treatment with desipramine and fluoxetine modulate BDNF, CaMKK α and CaMKK β mRNA levels in the hippocampus of transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuropharmacology, 2004, 47, 1062-1069.	4.1	50
266	Cellular changes in the postmortem hippocampus in major depression. Biological Psychiatry, 2004, 56, 640-650.	1.3	633
267	Alterations of neuroplasticity in depression: the hippocampus and beyond. European Neuropsychopharmacology, 2004, 14, S481-S490.	0.7	213
268	Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine. European Neuropsychopharmacology, 2004, 14, S497-S502.	0.7	144
269	A Role for Glia in the Action of Electroconvulsive Therapy. Harvard Review of Psychiatry, 2004, 12, 253-262.	2.1	20
270	Apoptotic Proteins in the Temporal Cortex in Schizophrenia: High Bax/Bcl-2 Ratio Without Caspase-3 Activation. American Journal of Psychiatry, 2004, 161, 109-115.	7.2	205
271	Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. International Journal of Neuropsychopharmacology, 2004, 7, 143-153.	2.1	76
272	Neurocognitive profiles in elderly patients with frontotemporal degeneration or major depressive disorder. Journal of the International Neuropsychological Society, 2004, 10, 753-771.	1.8	50
273	Protective and Damaging Effects of the Mediators of Stress and Adaptation: Allostasis and Allostatic Load. , 2004, , 65-98.		46
274	What's Missing in Posttraumatic Stress Disorder Research? Studies of Human Postmortem Tissue. Psychiatry (New York), 2004, 67, 398-403.	0.7	12

#	ARTICLE	IF	CITATIONS
275	Cell density and cortical thickness in Heschl's gyrus in schizophrenia, major depression and bipolar disorder. <i>British Journal of Psychiatry</i> , 2004, 185, 258-259.	2.8	38
276	Selective Neuron Loss in the Paraventricular Nucleus of Hypothalamus in Patients Suffering from Major Depression and Bipolar Disorder. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 224-229.	1.7	65
277	Neurobiological Background for Performing Surgical Intervention in the Inferior Thalamic Peduncle for Treatment of Major Depression Disorders. <i>Neurosurgery</i> , 2005, 57, 439-448.	1.1	75
278	Beyond Monoamines: Glutamatergic Function in Mood Disorders. <i>CNS Spectrums</i> , 2005, 10, 808-819.	1.2	254
280	Dominant "submissive behavior as models of mania and depression. <i>Neuroscience and Biobehavioral Reviews</i> , 2005, 29, 715-737.	6.1	116
281	Depression, the Perimenopause, and Estrogen Therapy. <i>Annals of the New York Academy of Sciences</i> , 2005, 1052, 27-40.	3.8	44
282	Depression in Epilepsy: A Neurobiologic Perspective. <i>Epilepsy Currents</i> , 2005, 5, 21-27.	0.8	146
283	Evidence for orbitofrontal pathology in bipolar disorder and major depression, but not in schizophrenia. <i>Bipolar Disorders</i> , 2005, 7, 358-369.	1.9	118
284	Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. <i>Molecular Psychiatry</i> , 2005, 10, 309-322.	7.9	363
285	The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. <i>Molecular Psychiatry</i> , 2005, 10, 105-116.	7.9	708
286	IDO and interferon- γ -induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. <i>Molecular Psychiatry</i> , 2005, 10, 538-544.	7.9	399
287	Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. <i>Molecular Psychiatry</i> , 2005, 10, 525-537.	7.9	103
288	Lower Packing Density of Glial Fibrillary Acidic Protein-Immunoreactive Astrocytes in the Prelimbic Cortex of Alcohol-Naive and Alcohol-Drinking Alcohol-Preferring Rats as Compared With Alcohol-Nonpreferring and Wistar Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2005, 29, 766-772.	2.4	48
289	Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. <i>Cellular Signalling</i> , 2005, 17, 549-557.	3.6	124
290	¹ H Magnetic resonance spectroscopy study of dorsolateral prefrontal cortex in unipolar mood disorder patients. <i>Psychiatry Research - Neuroimaging</i> , 2005, 138, 131-139.	1.8	37
291	Anatomical MRI study of corpus callosum in unipolar depression. <i>Journal of Psychiatric Research</i> , 2005, 39, 347-354.	3.1	85
292	Is vascular depression a distinct sub-type of depressive disorder? A review of causal evidence. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 1-11.	2.7	107
293	The Darwinian concept of stress: benefits of allostasis and costs of allostatic load and the trade-offs in health and disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2005, 29, 3-38.	6.1	933

#	ARTICLE	IF	CITATIONS
294	Volume deficits of subcortical nuclei in mood disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 401-412.	3.2	120
295	Consequences of large interindividual variability for human brain atlases: converging macroscopical imaging and microscopical neuroanatomy. <i>Anatomy and Embryology</i> , 2005, 210, 423-431.	1.5	115
298	Serotonin, dopamine, and cooperation. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	1
299	Modeling human behavioral traits and clarifying the construct of affiliation and its disorders. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	4
300	Is all affiliation the same? Facilitation or complementarity?. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	1
301	Trust: A temporary human attachment facilitated by oxytocin. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	28
302	The role of trait affiliation in human community. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	1
303	Opioid bliss as the felt hedonic core of mammalian prosociality “ and of consummatory pleasure more generally?. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	2
304	Affiliative reward and the ontogenetic bonding system. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	0
305	Mesolimbic-mesocortical loops may encode saliency, not just reward. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	1
306	Affiliative drive: Could this be disturbed in childhood autism?. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	0
307	Neuropeptides influence expression of and capacity to form social bonds. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	2
308	A nonhuman primate perspective on affiliation. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	0
309	Specificity of affiliation supported by neurotransmitter challenge tests and molecular genetics. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	0
310	Is the construct for human affiliation too narrow?. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	4
311	Integrating genetic, behavioral, and psychometric research in conceptualizing human behavioral traits. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	0
312	Endogenous and exogenous opiates modulate the development of parentâ€‘infant attachment. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	9
313	It's a long way up from comparative studies of animals to personality traits in humans. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	7

#	ARTICLE	IF	CITATIONS
314	Serotonin and affiliative behavior. Behavioral and Brain Sciences, 2005, 28, .	0.7	6
315	Impaired hedonic capacity in major depressive disorder: Impact on affiliative behaviors. Behavioral and Brain Sciences, 2005, 28, .	0.7	0
316	Social bonds, motivational conflict, and altruism: Implications for neurobiology. Behavioral and Brain Sciences, 2005, 28, .	0.7	2
317	Deficits in affiliative reward: An endophenotype for psychiatric disorders?. Behavioral and Brain Sciences, 2005, 28, .	0.7	3
318	Brain-Derived Neurotrophic Factor and Antidepressant Activity. Current Pharmaceutical Design, 2005, 11, 1495-1510.	1.9	147
319	The Concept of Dysregulated Signal Transduction and Gene Expression in the Pathophysiology of Mood Disorders. Current Psychiatry Reviews, 2005, 1, 227-254.	0.9	4
320	The Dual Transporter Inhibitor Duloxetine: A Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression. Current Pharmaceutical Design, 2005, 11, 1475-1493.	1.9	145
321	Electroconvulsive Seizure Treatment Increases Cell Proliferation in Rat Frontal Cortex. Neuropsychopharmacology, 2005, 30, 27-34.	5.4	120
322	A neurobehavioral model of affiliative bonding: Implications for conceptualizing a human trait of affiliation. Behavioral and Brain Sciences, 2005, 28, 313-50; discussion 350-95.	0.7	744
323	Affiliative bonding as a dynamical process: A view from ethology. Behavioral and Brain Sciences, 2005, 28, .	0.7	4
324	Increasing Hippocampal Neurogenesis: A Novel Mechanism for Antidepressant Drugs. Current Pharmaceutical Design, 2005, 11, 145-155.	1.9	144
325	Chronic Antidepressants Reduce Depolarization-Evoked Glutamate Release and Protein Interactions Favoring Formation of SNARE Complex in Hippocampus. Journal of Neuroscience, 2005, 25, 3270-3279.	3.6	219
326	Beyond affect: A role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12224-12229.	7.1	320
327	Depression in the elderly. Lancet, The, 2005, 365, 1961-1970.	13.7	1,425
328	Proton spectroscopy study of the left dorsolateral prefrontal cortex in pediatric depressed patients. Neuroscience Letters, 2005, 384, 321-326.	2.1	65
329	A novel neurological mechanism to explain the adverse effect of depression on coronary artery disease. Medical Hypotheses, 2005, 64, 284-287.	1.5	4
330	Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience, 2005, 133, 453-461.	2.3	184
331	In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. Neuroscience, 2005, 135, 927-937.	2.3	51

#	ARTICLE	IF	CITATIONS
332	Chronic stress impairs acoustic conditioning more than visual conditioning in rats: Morphological and behavioural evidence. <i>Neuroscience</i> , 2005, 135, 1067-1074.	2.3	35
333	Aging, stress and the hippocampus. <i>Ageing Research Reviews</i> , 2005, 4, 123-140.	10.9	182
334	GABA and glutamate systems as therapeutic targets in depression and mood disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 153-168.	3.4	131
335	Structural Brain Imaging Evidence for Multiple Pathological Processes at Different Stages of Brain Development in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2005, 31, 672-696.	4.3	479
336	Decreased Prefrontal Myo-Inositol in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2005, 57, 1526-1534.	1.3	153
337	Prominent Reduction in Pyramidal Neurons Density in the Orbitofrontal Cortex of Elderly Depressed Patients. <i>Biological Psychiatry</i> , 2005, 58, 297-306.	1.3	136
338	Late-Life Depression: A Model for Medical Classification. <i>Biological Psychiatry</i> , 2005, 58, 283-289.	1.3	64
339	Evidence for altered neuronal organisation within the planum temporale in major psychiatric disorders. <i>Schizophrenia Research</i> , 2005, 73, 69-78.	2.0	44
340	Unchanged packing density but altered size of neurofilament immunoreactive neurons in the prefrontal cortex in schizophrenia and major depression. <i>Schizophrenia Research</i> , 2005, 76, 159-171.	2.0	22
341	Overview of the field. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 5-9.	3.4	6
342	Depression, cytokines, and glial function. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 33-38.	3.4	64
343	Loving opioids in the brain. <i>Behavioral and Brain Sciences</i> , 2005, 28, .	0.7	1
346	A Neurotrophic Model for Stress-Related Mood Disorders. <i>Biological Psychiatry</i> , 2006, 59, 1116-1127.	1.3	2,873
347	Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. <i>NeuroImage</i> , 2006, 30, 485-497.	4.2	191
348	Neuroimmune–endocrine crosstalk in schizophrenia and mood disorders. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1017-1038.	2.8	59
349	Smaller Cingulate Volumes in Unipolar Depressed Patients. <i>Biological Psychiatry</i> , 2006, 59, 702-706.	1.3	142
350	Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder. <i>Biological Psychiatry</i> , 2006, 59, 1006-1020.	1.3	236
351	Misdiagnosis of the persistent postconcussion syndrome in patients with depression. <i>Archives of Clinical Neuropsychology</i> , 2006, 21, 303-310.	0.5	235

#	ARTICLE	IF	CITATIONS
352	The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress. Behavioural Brain Research, 2006, 175, 233-240.	2.2	129
353	Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neuroscience Letters, 2006, 395, 185-190.	2.1	54
354	Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neuroscience Letters, 2006, 404, 276-281.	2.1	85
355	Glial fibrillary acidic protein expression after electroconvulsive shocks in rat brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 663-667.	4.8	6
356	Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: Differential regulation of specific exons by antidepressants and corticosterone. Neuroscience, 2006, 139, 1017-1029.	2.3	180
357	Depression, SSRIs, and the Supposed Obligation to Suffer Mentally. Kennedy Institute of Ethics Journal, 2006, 16, 283-303.	0.5	7
358	Neuroimaging Abnormalities in the Amygdala in Mood Disorders. Annals of the New York Academy of Sciences, 2003, 985, 420-444.	3.8	447
359	A Novel Approach to the Identification of Psychiatric Drugs: Serotonin-Glutamate Interactions in the Prefrontal Cortex. CNS Neuroscience & Therapeutics, 2000, 6, 206-218.	4.0	4
360	Reduced Glial and Neuronal Packing Density in the Orbitofrontal Cortex in Alcohol Dependence and Its Relationship with Suicide and Duration of Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2006, 30, 1845-1855.	2.4	88
361	Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. Journal of Pineal Research, 2006, 40, 1-9.	7.4	186
362	ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. Molecular Psychiatry, 2006, 11, 86-98.	7.9	114
363	Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Molecular Psychiatry, 2006, 11, 663-679.	7.9	162
364	Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Molecular Psychiatry, 2006, 11, 965-978.	7.9	204
365	Plasticity of the Hippocampus: Adaptation to Chronic Stress and Allostatic Load. Annals of the New York Academy of Sciences, 2001, 933, 265-277.	3.8	706
366	Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets. NeuroRx, 2006, 3, 22-41.	6.0	134
367	Advances in the treatment of anxiety: Targeting glutamate. NeuroRx, 2006, 3, 57-68.	6.0	51
368	Volumetric brain imaging studies in the elderly with mood disorders. Current Psychiatry Reports, 2006, 8, 18-24.	4.5	5
369	The anatomy of co-morbid neuropsychiatric disorders based on cortico-limbic synaptic interactions. Neurotoxicity Research, 2006, 10, 65-85.	2.7	12

#	ARTICLE	IF	CITATIONS
370	Inflammation and depression: Is there a causal connection with dementia?. Neurotoxicity Research, 2006, 10, 149-160.	2.7	73
371	Hyperglycemic brain injury in the rat. Brain Research, 2006, 1076, 9-15.	2.2	38
372	Exposure to predator odor stress increases efflux of frontal cortex acetylcholine and monoamines in mice: Comparisons with immobilization stress and reversal by chlordiazepoxide. Brain Research, 2006, 1114, 24-30.	2.2	22
373	Epilepsy, suicidal behaviour, and depression: do they share common pathogenic mechanisms?. Lancet Neurology, The, 2006, 5, 107-108.	10.2	77
374	Our eyes: windows to our souls or crystal balls?. Lancet Neurology, The, 2006, 5, 108-110.	10.2	22
375	Effects of antidepressive therapy on auditory processing in severely depressed patients: A combined MRS and MEG study. Journal of Psychiatric Research, 2006, 40, 293-306.	3.1	34
376	Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, 110, 135-370.		483
377	Hippocampal neurogenesis: Opposing effects of stress and antidepressant treatment. Hippocampus, 2006, 16, 239-249.	1.9	663
379	HPA and Immune Axes in Stress: Involvement of the Serotonergic System. NeurolImmunoModulation, 2006, 13, 268-276.	1.8	107
380	Stress, the Hippocampus and the Hypothalamic-Pituitary-Adrenal Axis: Implications for the Development of Psychotic Disorders. Australian and New Zealand Journal of Psychiatry, 2006, 40, 725-741.	2.3	186
381	Astroglial Plasticity in the Hippocampus is Affected by Chronic Psychosocial Stress and Concomitant Fluoxetine Treatment. Neuropsychopharmacology, 2006, 31, 1616-1626.	5.4	388
382	The Ras-GRF1 Exchange Factor Coordinates Activation of H-Ras and Rac1 to Control Neuronal Morphology. Molecular Biology of the Cell, 2006, 17, 2177-2189.	2.1	30
383	The Cingulate as a Catalyst Region for Global Dysfunction: a Dynamical Modelling Paradigm. Cerebral Cortex, 2006, 16, 1212-1224.	2.9	6
384	GABAergic Neurons Immunoreactive for Calcium Binding Proteins are Reduced in the Prefrontal Cortex in Major Depression. Neuropsychopharmacology, 2007, 32, 471-482.	5.4	354
385	Gene Expression Profiling in Postmortem Prefrontal Cortex of Major Depressive Disorder. Journal of Neuroscience, 2007, 27, 13329-13340.	3.6	113
386	Role of psychiatric comorbidity on cognitive function during and after the menopausal transition. Expert Review of Neurotherapeutics, 2007, 7, S157-S180.	2.8	8
387	Reduced Prefrontal Glutamate/Glutamine and \hat{I}^3 -Aminobutyric Acid Levels in Major Depression Determined Using Proton Magnetic Resonance Spectroscopy. Archives of General Psychiatry, 2007, 64, 193.	12.3	746
388	Chronic Fluoxetine Treatment Increases the Expression of PSA-NCAM in the Medial Prefrontal Cortex. Neuropsychopharmacology, 2007, 32, 803-812.	5.4	90

#	ARTICLE	IF	CITATIONS
389	Comorbid anxiety corresponds with neuropsychological dysfunction in unipolar depression. <i>Cognitive Neuropsychiatry</i> , 2007, 12, 437-456.	1.3	66
390	Chronic Duloxetine Treatment Induces Specific Changes in the Expression of BDNF Transcripts and in the Subcellular Localization of the Neurotrophin Protein. <i>Neuropsychopharmacology</i> , 2007, 32, 2351-2359.	5.4	110
391	Morphology of Pyramidal Neurons in the Rat Prefrontal Cortex: Lateralized Dendritic Remodeling by Chronic Stress. <i>Neural Plasticity</i> , 2007, 2007, 1-14.	2.2	66
393	The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. <i>Behavioural Pharmacology</i> , 2007, 18, 391-418.	1.7	592
394	Targeting Neurotrophic/Growth Factor Expression and Signaling for Antidepressant Drug Development. <i>CNS and Neurological Disorders - Drug Targets</i> , 2007, 6, 151-160.	1.4	52
395	Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies?. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 547.	2.1	128
396	Orbitofrontal cortex volume in late life depression: influence of hyperintense lesions and genetic polymorphisms. <i>Psychological Medicine</i> , 2007, 37, 1763-1773.	4.5	102
397	Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder—a postmortem study. <i>Psychiatry Research</i> , 2007, 151, 145-150.	3.3	166
398	Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. <i>Neuroscience</i> , 2007, 144, 368-374.	2.3	187
399	Social neuroscience of child and adolescent depression. <i>Brain and Cognition</i> , 2007, 65, 47-68.	1.8	32
400	Distribution of ICAM-1 immunoreactivity during aging in the human orbitofrontal cortex. <i>Brain, Behavior, and Immunity</i> , 2007, 21, 100-111.	4.1	25
401	Expression analysis of actin-related genes as an underlying mechanism for mood disorders. <i>Biochemical and Biophysical Research Communications</i> , 2007, 352, 780-786.	2.1	23
402	PSA-NCAM expression in the human prefrontal cortex. <i>Journal of Chemical Neuroanatomy</i> , 2007, 33, 202-209.	2.1	47
403	Major depressive disorder viewed as a dysfunction in astroglial bioenergetics. <i>Medical Hypotheses</i> , 2007, 68, 370-377.	1.5	27
404	The tripartite synapse: roles for gliotransmission in health and disease. <i>Trends in Molecular Medicine</i> , 2007, 13, 54-63.	6.7	717
405	Prospective reports of chronic life stress predict decreased grey matter volume in the hippocampus. <i>NeuroImage</i> , 2007, 35, 795-803.	4.2	264
406	Hypothèses neuro-développementales de la dépression. <i>L'Encephale</i> , 2007, 33, 655-660.	0.9	0
407	A Model for the Involvement of Neural Cell Adhesion Molecules in Stress-Related Mood Disorders. <i>Neuroendocrinology</i> , 2007, 85, 158-176.	2.5	70

#	ARTICLE	IF	CITATIONS
408	The contribution of pre-existing depression to the acute cognitive sequelae of mild traumatic brain injury. <i>Brain Injury</i> , 2007, 21, 951-961.	1.2	18
409	Chronic Social Stress Inhibits Cell Proliferation in the Adult Medial Prefrontal Cortex: Hemispheric Asymmetry and Reversal by Fluoxetine Treatment. <i>Neuropsychopharmacology</i> , 2007, 32, 1490-1503.	5.4	314
410	Brain Correlates of Antidepressant Treatment Outcome from Neuroimaging Studies in Depression. <i>Psychiatric Clinics of North America</i> , 2007, 30, 91-103.	1.3	32
411	Neuroanatomical Characteristics of Geriatric Apathy and Depression: A Magnetic Resonance Imaging Study. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 386-394.	1.2	125
412	Regional Cerebral Glucose Metabolic Abnormalities in Bipolar II Depression. <i>Biological Psychiatry</i> , 2007, 61, 765-775.	1.3	114
413	Selective Deficits in the Omega-3 Fatty Acid Docosahexaenoic Acid in the Postmortem Orbitofrontal Cortex of Patients with Major Depressive Disorder. <i>Biological Psychiatry</i> , 2007, 62, 17-24.	1.3	229
414	Chronic Unpredictable Stress Decreases Cell Proliferation in the Cerebral Cortex of the Adult Rat. <i>Biological Psychiatry</i> , 2007, 62, 496-504.	1.3	308
416	Glutogenesis and Glial Pathology in Depression. <i>CNS and Neurological Disorders - Drug Targets</i> , 2007, 6, 219-233.	1.4	510
417	Norepinephrine and cognitive disorders. , 2007, , 408-435.		5
418	Role of GABA in anxiety and depression. <i>Depression and Anxiety</i> , 2007, 24, 495-517.	4.1	416
419	GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2007, 31, 920-931.	6.1	134
420	Variation of the choline signal intensity in the dorsolateral prefrontal cortex of rats exposed to the forced swimming test as detected by in vivo 1H MR spectroscopy. <i>Journal of Neuroscience Methods</i> , 2007, 165, 89-94.	2.5	11
421	Prefrontal hyperactivation during working memory task in untreated individuals with major depressive disorder. <i>Molecular Psychiatry</i> , 2007, 12, 158-166.	7.9	211
422	The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. <i>Molecular Psychiatry</i> , 2007, 12, 988-1000.	7.9	570
423	Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment. <i>European Journal of Neuroscience</i> , 2007, 25, 3109-3114.	2.6	168
424	From the Golgi to Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: Wiring and volume transmission. <i>Brain Research Reviews</i> , 2007, 55, 17-54.	9.0	205
425	Kynurenine pathway in major depression: Evidence of impaired neuroprotection. <i>Journal of Affective Disorders</i> , 2007, 98, 143-151.	4.1	470
426	Causality of stem cell based neurogenesis and depression – To be or not to be, is that the question?. <i>Journal of Psychiatric Research</i> , 2007, 41, 713-723.	3.1	24

#	ARTICLE	IF	CITATIONS
427	Orbitofrontal Cortex Function and Structure in Depression. <i>Annals of the New York Academy of Sciences</i> , 2007, 1121, 499-527.	3.8	342
428	Comorbidity implications in brain disease: Neuronal substrates of symptom profiles. <i>Neurotoxicity Research</i> , 2007, 12, 1-15.	2.7	11
429	Glia mechanisms in mood regulation: a novel model of mood disorders. <i>Psychopharmacology</i> , 2007, 191, 55-65.	3.1	58
431	Imaging the neurobiological substrate of atypical depression by SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 110-120.	6.4	10
432	Segmentation of arteries in MPRAGE images of the ventral medial prefrontal cortex. <i>Computerized Medical Imaging and Graphics</i> , 2008, 32, 36-43.	5.8	6
433	BDNF Level in the Rat Prefrontal Cortex Increases Following Chronic but Not Acute Treatment with Duloxetine, a Dual Acting Inhibitor of Noradrenaline and Serotonin Re-uptake. <i>Cellular and Molecular Neurobiology</i> , 2008, 28, 457-468.	3.3	51
434	Neurophysiological and neurochemical aspects of the effects of antidepressants and mood stabilizers. <i>Neurophysiology</i> , 2008, 40, 64-78.	0.3	2
435	Cerebral Metabolic Changes in a Depression-like Rat Model of Chronic Forced Swimming Studied by Ex Vivo High Resolution 1H Magnetic Resonance Spectroscopy. <i>Neurochemical Research</i> , 2008, 33, 2342-2349.	3.3	40
436	Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. <i>Brain Structure and Function</i> , 2008, 213, 93-118.	2.3	1,801
437	Mourning and melancholia revisited: correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry. <i>Annals of General Psychiatry</i> , 2008, 7, 9.	2.7	81
438	Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. <i>Journal of Neurochemistry</i> , 2008, 79, 25-34.	3.9	122
439	Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. <i>Journal of Neurochemistry</i> , 2008, 79, 826-834.	3.9	87
440	Effects of the G(-656)A variant on CREB1 promoter activity in a glial cell line: Interactions with gonadal steroids and stress. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 579-585.	1.7	11
441	Stress and glucocorticoid footprints in the brain – The path from depression to Alzheimer's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2008, 32, 1161-1173.	6.1	88
442	Large-scale estimates of cellular origins of mRNAs: Enhancing the yield of transcriptome analyses. <i>Journal of Neuroscience Methods</i> , 2008, 167, 198-206.	2.5	13
443	Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms. <i>Neuropsychopharmacology</i> , 2008, 33, 88-109.	5.4	1,488
444	Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 380-386.	4.5	48
445	Absence and size of massa intermedia in patients with schizophrenia and bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2008, 20, 193-198.	2.1	23

#	ARTICLE	IF	CITATIONS
446	Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 426-437.	46.4	761
447	Early intervention in bipolar disorder, part I: clinical and imaging findings. <i>Microbial Biotechnology</i> , 2008, 2, 122-135.	1.7	24
448	Dopamine receptor gene expression in human amygdaloid nuclei: Elevated D4 receptor mRNA in major depression. <i>Brain Research</i> , 2008, 1207, 214-224.	2.2	49
449	The As and Ds of stress: Metabolic, morphological and behavioral consequences. <i>European Journal of Pharmacology</i> , 2008, 585, 64-75.	3.5	95
450	Norepinephrine-glucocorticoids interaction does not annul the opposite effects of the individual treatments on cellular plasticity in neuroblastoma cells. <i>European Journal of Pharmacology</i> , 2008, 596, 14-24.	3.5	16
451	Serum markers support disease-specific glial pathology in major depression. <i>Journal of Affective Disorders</i> , 2008, 111, 271-280.	4.1	132
452	Altered expression of neurotrophic factors in patients with major depression. <i>Journal of Psychiatric Research</i> , 2008, 42, 1145-1153.	3.1	150
453	Interregional cerebral metabolic associativity during a continuous performance task (Part II) : Differential alterations in bipolar and unipolar disorders. <i>Psychiatry Research - Neuroimaging</i> , 2008, 164, 30-47.	1.8	31
454	Glucose metabolic changes in the prefrontal cortex are associated with HPA axis response to a psychosocial stressor. <i>Psychoneuroendocrinology</i> , 2008, 33, 517-529.	2.7	199
455	Effects of mental illness and aging in two thalamic nuclei. <i>Schizophrenia Research</i> , 2008, 106, 172-181.	2.0	27
456	Intracranial current density (LORETA) differences in QEEG frequency bands between depressed and non-depressed alcoholic patients. <i>Clinical Neurophysiology</i> , 2008, 119, 948-958.	1.5	25
457	Von Economo neurons are present in the dorsolateral (dysgranular) prefrontal cortex of humans. <i>Neuroscience Letters</i> , 2008, 435, 215-218.	2.1	88
458	Bioenergetics of cerebral ischemia: A cellular perspective. <i>Neuropharmacology</i> , 2008, 55, 289-309.	4.1	169
459	The neurobiology of retinoic acid in affective disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 315-331.	4.8	139
460	Electroencephalographic differences between depressed and control subjects: An aspect of interdependence analysis. <i>Brain Research Bulletin</i> , 2008, 76, 559-564.	3.0	48
461	Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: A comparative post-mortem study. <i>European Psychiatry</i> , 2008, 23, 413-420.	0.2	68
462	Neurobiological and Clinical Effects of the Antidepressant Tianeptine. <i>CNS Drugs</i> , 2008, 22, 15-26.	5.9	281
463	Riluzole in the Treatment of Mood and Anxiety Disorders. <i>CNS Drugs</i> , 2008, 22, 761-786.	5.9	150

#	ARTICLE	IF	CITATIONS
464	Dual Constraints on Synapse Formation and Regression in Schizophrenia: Neuregulin, Neuroligin, Dysbindin, DISC1, MuSK and Agrin. Australian and New Zealand Journal of Psychiatry, 2008, 42, 662-677.	2.3	30
465	A novel transcutaneous vagus nerve stimulation leads to brainstem and cerebral activations measured by functional MRI / Funktionelle Magnetresonanztomographie zeigt Aktivierungen des Hirnstamms und weiterer zerebraler Strukturen unter transkutaner Vagusnervstimulation. Biomedizinische Technik. 2008. 53. 104-111.	0.8	211
466	p21Cip1 restricts neuronal proliferation in the subgranular zone of the dentate gyrus of the hippocampus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1358-1363.	7.1	94
467	Repeated Unpredictable Stress and Antidepressants Differentially Regulate Expression of the Bcl-2 Family of Apoptotic Genes in Rat Cortical, Hippocampal, and Limbic Brain Structures. Neuropsychopharmacology, 2008, 33, 1545-1558.	5.4	141
468	Divergent Plasticity of Prefrontal Cortex Networks. Neuropsychopharmacology, 2008, 33, 42-55.	5.4	89
469	Lower Phosphoinositide 3-Kinase (PI 3-kinase) Activity and Differential Expression Levels of Selective Catalytic and Regulatory PI 3-Kinase Subunit Isoforms in Prefrontal Cortex and Hippocampus of Suicide Subjects. Neuropsychopharmacology, 2008, 33, 2324-2340.	5.4	32
470	Biological basis for the surgical treatment of depression. Neurosurgical Focus, 2008, 25, E2.	2.3	25
471	Orbitofrontal Cortex Volumes in Medication Naïve Children with Major Depressive Disorder: A Magnetic Resonance Imaging Study. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 551-556.	1.3	14
472	Gene Expression Profiling Reveals Complex Changes in the Olfactory Bulbectomy Model of Depression After Chronic Treatment With Antidepressants. Journal of Pharmacological Sciences, 2008, 108, 320-334.	2.5	12
473	The Subgenual Anterior Cingulate Cortex in Mood Disorders. CNS Spectrums, 2008, 13, 663-681.	1.2	920
474	COX-2 Inhibition in Schizophrenia and Major Depression. Current Pharmaceutical Design, 2008, 14, 1452-1465.	1.9	94
475	Alterations in Neural Structures as Risk Factors for Depression. , 2008, , 37-61.		0
476	Is Depression in Epilepsy the Expression of a Neurological Disorder?. , 2008, , 67-87.		1
477	Malfunction in GABA and Glutamate as Pathways to Depression: A Review of the Evidence. Clinical Medicine Therapeutics, 2009, 1, CMT.S3481.	0.1	2
478	Depression and pain. Frontiers in Bioscience - Landmark, 2009, 14, 5031.	3.0	130
479	The Role of Glial Cells in Drug Abuse. Current Drug Abuse Reviews, 2009, 2, 76-82.	3.4	117
480	Neurobiology of depression, fibromyalgia and neuropathic pain. Frontiers in Bioscience - Landmark, 2009, 14, 5291.	3.0	279
481	Research advances in geriatric depression. World Psychiatry, 2009, 8, 140-149.	10.4	72

#	ARTICLE	IF	CITATIONS
482	Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis and Pharmacotherapy. , 2009, , .		5
483	Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. International Journal of Neuropsychopharmacology, 2009, 12, 155.	2.1	71
484	Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. International Journal of Neuropsychopharmacology, 2009, 12, 143.	2.1	116
485	Corticolimbic Transcriptome Changes are State-Dependent and Region-Specific in a Rodent Model of Depression and of Antidepressant Reversal. Neuropsychopharmacology, 2009, 34, 1363-1380.	5.4	173
486	The Relationship Between Aberrant Neuronal Activation in the Pregenuel Anterior Cingulate, Altered Glutamatergic Metabolism, and Anhedonia in Major Depression. Archives of General Psychiatry, 2009, 66, 478.	12.3	278
487	Mammillary bodies and fornix fibers are injured in heart failure. Neurobiology of Disease, 2009, 33, 236-242.	4.4	85
488	Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression. Psychiatry Research - Neuroimaging, 2009, 172, 49-54.	1.8	38
489	An MRI-based approach for the measurement of the dorsolateral prefrontal cortex in humans. Psychiatry Research - Neuroimaging, 2009, 173, 150-154.	1.8	17
490	Normal metabolite levels in the left dorsolateral prefrontal cortex of unmedicated major depressive disorder patients: A single voxel 1H spectroscopy study. Psychiatry Research - Neuroimaging, 2009, 174, 177-183.	1.8	62
491	Antagonist but not agonist labeling of serotonin-1A receptors is decreased in major depressive disorder. Journal of Psychiatric Research, 2009, 43, 887-894.	3.1	38
492	Through the looking glass: Examining neuroanatomical evidence for cellular alterations in major depression. Journal of Psychiatric Research, 2009, 43, 947-961.	3.1	129
493	Decreased glutamic acid decarboxylase67 mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. Journal of Psychiatric Research, 2009, 43, 970-977.	3.1	166
494	Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today, 2009, 14, 690-697.	6.4	60
495	Structural brain abnormalities in major depressive disorder: A selective review of recent MRI studies. Journal of Affective Disorders, 2009, 117, 1-17.	4.1	519
496	Demonstration of disturbed activity of orbitofrontal pyramidal neurons in depressed patients by the AgNOR staining method. Journal of Affective Disorders, 2009, 118, 131-138.	4.1	13
497	Prefrontal brain morphology and executive function in healthy and depressed elderly. International Journal of Geriatric Psychiatry, 2009, 24, 459-468.	2.7	58
498	Reductions in neuronal density in elderly depressed are region specific. International Journal of Geriatric Psychiatry, 2009, 24, 856-864.	2.7	22
499	The psychoneuroimmunology of depression. Human Psychopharmacology, 2009, 24, 165-175.	1.5	167

#	ARTICLE	IF	CITATIONS
500	Neuropsychiatric disorders related to interferon and interleukins treatment. Metabolic Brain Disease, 2009, 24, 55-68.	2.9	102
501	Macroscopic brain architecture changes and white matter pathology in acromegaly: a clinicoradiological study. Pituitary, 2009, 12, 177-185.	2.9	37
502	Frontal Atrophy and Attention Deficits in Older Adults with a History of Elevated Depressive Symptoms. Brain Imaging and Behavior, 2009, 3, 358-369.	2.1	11
503	Antidepressant effect detected on proton magnetic resonance spectroscopy in drug-naïve female patients with first-episode major depression. Psychiatry and Clinical Neurosciences, 2009, 63, 350-356.	1.8	53
504	Temporal lobe epilepsy, depression, and hippocampal volume. Epilepsia, 2009, 50, 1067-1071.	5.1	62
505	Bipolar and major depressive disorder: Neuroimaging the developmental-degenerative divide. Neuroscience and Biobehavioral Reviews, 2009, 33, 699-771.	6.1	433
506	Gonadal Hormones and Behavior in Women: Concentrations versus Context. , 2009, , 2395-2430.		2
507	A role for the extracellular signal-regulated kinase signal pathway in depressive-like behavior. Behavioural Brain Research, 2009, 199, 203-209.	2.2	72
508	Region specific decrease in glial fibrillary acidic protein immunoreactivity in the brain of a rat model of depression. Neuroscience, 2009, 159, 915-925.	2.3	137
509	Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience, 2009, 164, 300-330.	2.3	198
510	Differential regulation of the serotonin 1 A transcriptional modulators five prime repressor element under dual repression-1 and nuclear-deformed epidermal autoregulatory factor by chronic stress. Neuroscience, 2009, 163, 1119-1127.	2.3	26
511	Suicide neurobiology. Progress in Neurobiology, 2009, 89, 315-333.	5.7	161
512	Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 70-75.	4.8	340
513	Strain differences in the distribution of N-methyl-d-aspartate and gamma (Î³)-aminobutyric acid-A receptors in rat brain. Life Sciences, 2009, 85, 794-799.	4.3	26
514	Neurophysiological mechanisms of electroconvulsive therapy for depression. Neuroscience Research, 2009, 64, 3-11.	1.9	55
515	Two-dimensional assessment of cytoarchitecture in the superior temporal white matter in schizophrenia, major depressive disorder and bipolar disorder. Schizophrenia Research, 2009, 115, 156-162.	2.0	38
516	Depression and Epilepsy: A Review of Multiple Facets of Their Close Relation. Neurologic Clinics, 2009, 27, 865-880.	1.8	153
517	Clomipramine treatment reversed the glial pathology in a chronic unpredictable stress-induced rat model of depression. European Neuropsychopharmacology, 2009, 19, 796-805.	0.7	74

#	ARTICLE	IF	CITATIONS
518	Prenatal stress decreases glycogen synthase kinase-3 phosphorylation in the rat frontal cortex. Pharmacological Reports, 2009, 61, 612-620.	3.3	29
519	Decreased gyrification in major depressive disorder. NeuroReport, 2009, 20, 378-380.	1.2	55
520	Morphometric changes in early- and late-life major depressive disorder: evidence from postmortem studies. International Psychogeriatrics, 2009, 21, 844.	1.0	42
521	Morphometric analysis of neuronal and glial cell pathology in the dorsolateral prefrontal cortex in late-life depression. British Journal of Psychiatry, 2009, 195, 163-169.	2.8	59
522	Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System. Current Psychiatry Reviews, 2009, 5, 287-297.	0.9	16
523	Postnatal Brain Development and Psychotropic Drugs. Effects on Animals and Animal Models of Depression and Attention-Deficit/Hyperactivity Disorder. Current Pharmaceutical Design, 2010, 16, 2474-2483.	1.9	6
524	Network models of psychopathology and comorbidity: Philosophical and pragmatic considerations. Behavioral and Brain Sciences, 2010, 33, 159-160.	0.7	3
525	Network origins of anxiety and depression. Behavioral and Brain Sciences, 2010, 33, 161-162.	0.7	6
526	Toward scientifically useful quantitative models of psychopathology: The importance of a comparative approach. Behavioral and Brain Sciences, 2010, 33, 163-164.	0.7	17
527	Comorbidity: Cognition and biology count!. Behavioral and Brain Sciences, 2010, 33, 168-170.	0.7	4
528	The missing developmental dimension in the network perspective. Behavioral and Brain Sciences, 2010, 33, 175-176.	0.7	4
529	Visualizing genetic similarity at the symptom level: The example of learning disabilities. Behavioral and Brain Sciences, 2010, 33, 155-157.	0.7	0
530	Symptom networks and psychiatric categories. Behavioral and Brain Sciences, 2010, 33, 158-159.	0.7	6
531	Looking at comorbidity through the glasses of neuroscientific memory research: A brain-network perspective. Behavioral and Brain Sciences, 2010, 33, 170-171.	0.7	4
532	The importance of modeling comorbidity using an intra-individual, time-series approach. Behavioral and Brain Sciences, 2010, 33, 172-173.	0.7	7
533	The abandonment of latent variables: Philosophical considerations. Behavioral and Brain Sciences, 2010, 33, 177-178.	0.7	5
534	The rocky road from Axis I to Axis II: Extending the network model of diagnostic comorbidity to personality pathology. Behavioral and Brain Sciences, 2010, 33, 151-152.	0.7	4
535	Comorbid science?. Behavioral and Brain Sciences, 2010, 33, 153-155.	0.7	6

#	ARTICLE	IF	CITATIONS
536	The network perspective will help, but is comorbidity the question?. Behavioral and Brain Sciences, 2010, 33, 162-163.	0.7	1
537	Questions about networks, measurement, and causation. Behavioral and Brain Sciences, 2010, 33, 164-165.	0.7	3
538	Comorbidity: The case of developmental psychopathology. Behavioral and Brain Sciences, 2010, 33, 167-168.	0.7	7
539	Consequences of a network view for genetic association studies. Behavioral and Brain Sciences, 2010, 33, 173-174.	0.7	4
540	Aligning psychological assessment with psychological science. Behavioral and Brain Sciences, 2010, 33, 152-153.	0.7	4
541	An agenda for symptom-based research. Behavioral and Brain Sciences, 2010, 33, 157-157.	0.7	9
542	Extending the network perspective on comorbidity. Behavioral and Brain Sciences, 2010, 33, 158-158.	0.7	9
543	Networks as complex dynamic systems: Applications to clinical and developmental psychology and psychopathology. Behavioral and Brain Sciences, 2010, 33, 174-175.	0.7	5
544	Comorbidity in the context of neural network properties. Behavioral and Brain Sciences, 2010, 33, 176-177.	0.7	8
545	Complex realities require complex theories: Refining and extending the network approach to mental disorders. Behavioral and Brain Sciences, 2010, 33, 178-193.	0.7	89
546	Symptoms as latent variables. Behavioral and Brain Sciences, 2010, 33, 165-166.	0.7	8
547	DHA Deficiency and Prefrontal Cortex Neuropathology in Recurrent Affective Disorders. Journal of Nutrition, 2010, 140, 864-868.	2.9	58
548	Sleep Pathologies in Depression and the Clinical Utility of Polysomnography. Canadian Journal of Psychiatry, 2010, 55, 413-421.	1.9	34
550	How Late-Life Depression Affects Cognition: Neural Mechanisms. Current Psychiatry Reports, 2010, 12, 34-38.	4.5	68
551	Effects of Depressive-Like Behavior of Rats on Brain Glutamate Uptake. Neurochemical Research, 2010, 35, 1164-1171.	3.3	41
552	Grey matter volume reductions in the emotion network of patients with depression and coronary artery disease. Psychiatry Research - Neuroimaging, 2010, 181, 9-14.	1.8	16
553	A time-saving and facilitating approach for segmentation of anatomically defined cortical regions: MRI volumetry. Psychiatry Research - Neuroimaging, 2010, 181, 211-218.	1.8	12
554	3-D Cytoarchitectonic parcellation of human orbitofrontal cortex. Psychiatry Research - Neuroimaging, 2010, 183, 1-20.	1.8	58

#	ARTICLE	IF	CITATIONS
555	Reduced medial prefrontal N-Acetyl-Aspartate levels in pediatric major depressive disorder: A multi-voxel in vivo 1H spectroscopy study. <i>Psychiatry Research - Neuroimaging</i> , 2010, 184, 71-76.	1.8	32
556	Trait and state dependent functional impairments in bipolar disorder. <i>Psychiatry Research - Neuroimaging</i> , 2010, 184, 135-142.	1.8	43
557	Depression research: where are we now?. <i>Molecular Brain</i> , 2010, 3, 8.	2.6	121
558	Neuroglia in neurodegeneration. <i>Brain Research Reviews</i> , 2010, 63, 189-211.	9.0	247
559	Altered expression of lipid metabolism and immune response genes in the frontal cortex of suicide completers. <i>Journal of Affective Disorders</i> , 2010, 120, 24-31.	4.1	51
560	Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. <i>Journal of Affective Disorders</i> , 2010, 127, 230-240.	4.1	190
561	Hippocampal astrocytes are necessary for antidepressant treatment of learned helplessness rats. <i>Hippocampus</i> , 2011, 21, 877-884.	1.9	50
562	Effects of the A(â~115)G variant on <i>CREB1</i> promoter activity in two brain cell lines: Interactions with gonadal steroids. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1365-1372.	1.7	9
563	Neuropathological analysis of lacunes and microvascular lesions in late-onset depression. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 661-672.	3.2	30
564	Cortical and subcortical white matter abnormalities in adults with remitted firstâ€episode mania revealed by Tractâ€Based Spatial Statistics. <i>Bipolar Disorders</i> , 2010, 12, 383-389.	1.9	48
565	Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. <i>Bipolar Disorders</i> , 2010, 12, 541-549.	1.9	136
566	Frontal lobe. , 0, , 84-121.		1
567	Neural stem cell regulation, fibroblast growth factors, and the developmental origins of neuropsychiatric disorders. <i>Frontiers in Neuroscience</i> , 2010, 4, .	2.8	48
568	Densidad Neuronal en la Corteza Visual Primaria (Ãrea 17), en Ratas Sometidas a EstrÃ©s CrÃ³nico. <i>International Journal of Morphology</i> , 2010, 28, .	0.2	0
569	The Concept of Depression as a Dysfunction of the Immune System. <i>Current Immunology Reviews</i> , 2010, 6, 205-212.	1.2	217
570	Some mental disorders are based on networks, others on latent variables. <i>Behavioral and Brain Sciences</i> , 2010, 33, 166-167.	0.7	2
571	Comorbidity: A network perspective. <i>Behavioral and Brain Sciences</i> , 2010, 33, 137-150.	0.7	1,043
572	Decreased expression of Freud-1/CC2D1A, a transcriptional repressor of the 5-HT1A receptor, in the prefrontal cortex of subjects with major depression. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 1089-1101.	2.1	32

#	ARTICLE	IF	CITATIONS
573	Is there a contradiction between the network and latent variable perspectives?. Behavioral and Brain Sciences, 2010, 33, 160-161.	0.7	9
574	Peripheral BDNF Produces Antidepressant-Like Effects in Cellular and Behavioral Models. Neuropsychopharmacology, 2010, 35, 2378-2391.	5.4	350
575	Latent variable models are network models. Behavioral and Brain Sciences, 2010, 33, 166-166.	0.7	23
576	Latent variables and the network perspective. Behavioral and Brain Sciences, 2010, 33, 150-151.	0.7	35
577	Mood and Neurobehavioral Correlates of Cerebellar Lesions. Cognitive and Behavioral Neurology, 2010, 23, 63-73.	0.9	10
578	Mood Disorders Are Glial Disorders: Evidence from In Vivo Studies. Cardiovascular Psychiatry and Neurology, 2010, 2010, 1-7.	0.8	61
580	PATHOPHYSIOLOGY OF DEPRESSION: DO WE HAVE ANY SOLID EVIDENCE OF INTEREST TO CLINICIANS?. World Psychiatry, 2010, 9, 155-161.	10.4	381
581	Pharmacogenomics of Mood Stabilizers in the Treatment of Bipolar Disorder. Human Genomics and Proteomics, 2010, 2, 159761.	1.5	19
582	Enhanced Function of Prefrontal Serotonin 5-HT ₂ Receptors in a Rat Model of Psychiatric Vulnerability. Journal of Neuroscience, 2010, 30, 12138-12150.	3.6	78
583	Impact of the Hypothalamic-pituitary-adrenal/gonadal Axes on Trajectory of Age-Related Cognitive Decline. Progress in Brain Research, 2010, 182, 31-76.	1.4	62
584	Blockade of Astrocytic Glutamate Uptake in Rats Induces Signs of Anhedonia and Impaired Spatial Memory. Neuropsychopharmacology, 2010, 35, 2049-2059.	5.4	136
585	Glutamatergic and resting state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula. Frontiers in Systems Neuroscience, 2010, 4, .	2.5	150
586	Vascular depression. An age-related mood disorder. European Geriatric Medicine, 2010, 1, 220-225.	2.8	11
587	Reduced Density of Calbindin Immunoreactive GABAergic Neurons in the Occipital Cortex in Major Depression: Relevance to Neuroimaging Studies. Biological Psychiatry, 2010, 67, 465-470.	1.3	144
588	Modulation in Activation and Expression of Phosphatase and Tensin Homolog on Chromosome Ten, Akt1, and 3-Phosphoinositide-Dependent Kinase 1: Further Evidence Demonstrating Altered Phosphoinositide 3-Kinase Signaling in Postmortem Brain of Suicide Subjects. Biological Psychiatry, 2010, 67, 1017-1025.	1.3	46
589	Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders. Biological Psychiatry, 2010, 68, 785-794.	1.3	424
590	mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists. Science, 2010, 329, 959-964.	12.6	2,377
591	Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 279-283.	4.8	101

#	ARTICLE	IF	CITATIONS
592	The association between serum levels of neopterin and number of depressive episodes of major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 372-375.	4.8	64
593	High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1189-1195.	4.8	59
594	Effects of neonatal flutamide treatment on hippocampal neurogenesis and synaptogenesis correlate with depression-like behaviors in preadolescent male rats. Neuroscience, 2010, 169, 544-554.	2.3	48
595	Analysis of two polymorphisms of the manganese superoxide dismutase gene (Ile-58Thr and Ala-9Val) in patients with recurrent depressive disorder. Psychiatry Research, 2010, 179, 43-46.	3.3	30
596	Neuroimaging changes in mesial temporal lobe epilepsy are magnified in the presence of depression. Epilepsy and Behavior, 2010, 19, 422-427.	1.7	46
597	Cortical thickness and voxel-based morphometry in depressed elderly. European Neuropsychopharmacology, 2010, 20, 398-404.	0.7	50
598	Multiple Sclerosis and Depression: A Neuroimmunological Perspective. Neurolmmune Biology, 2010, , 269-307.	0.2	1
599	Mechanisms of Synapse and Dendrite Maintenance and Their Disruption in Psychiatric and Neurodegenerative Disorders. Annual Review of Neuroscience, 2010, 33, 349-378.	10.7	217
600	Recent advances in (patho)physiology of astroglia. Acta Pharmacologica Sinica, 2010, 31, 1044-1054.	6.1	57
601	The Concept of Depression as a Dysfunction of the Immune System. Modern Problems of Pharmacopsychiatry, 2010, , 53-71.	2.5	15
602	Valproate and Amitriptyline Exert Common and Divergent Influences on Global and Gene Promoter-Specific Chromatin Modifications in Rat Primary Astrocytes. Neuropsychopharmacology, 2010, 35, 792-805.	5.4	112
603	Neurocircuitry of Mood Disorders. Neuropsychopharmacology, 2010, 35, 192-216.	5.4	1,326
604	Antidepressants in counselling psychology: Relevance, effectiveness and implications for practice. Counselling Psychology Quarterly, 2011, 24, 139-156.	2.3	0
605	Morphometric Analysis of Neuronal and Glial Cell Pathology in the Caudate Nucleus in Late-Life Depression. American Journal of Geriatric Psychiatry, 2011, 19, 132-141.	1.2	36
606	Abnormal Cingulate and Prefrontal Cortical Neurochemistry in Major Depression After Electroconvulsive Therapy. Biological Psychiatry, 2011, 69, 772-779.	1.3	92
607	The Subcallosal Cingulate Gyrus in the Context of Major Depression. Biological Psychiatry, 2011, 69, 301-308.	1.3	404
608	Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure. Biological Psychiatry, 2011, 69, 754-761.	1.3	936
609	Identification of Neural Targets for the Treatment of Psychiatric Disorders: The Role of Functional Neuroimaging. Neurosurgery Clinics of North America, 2011, 22, 279-305.	1.7	7

#	ARTICLE	IF	CITATIONS
610	Antidepressants elevate GDNF expression and release from C6 glioma cells in a β 2-arrestin1-dependent, CREB interactive pathway. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 1289-1300.	2.1	41
611	Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. <i>NeuroImage</i> , 2011, 54, 2643-2651.	4.2	170
612	Astrocytic Hypertrophy in Anterior Cingulate White Matter of Depressed Suicides. <i>Neuropsychopharmacology</i> , 2011, 36, 2650-2658.	5.4	185
613	Microinjection of valproic acid into the ventrolateral orbital cortex exerts an antidepressant-like effect in the rat forced swim test. <i>Brain Research Bulletin</i> , 2011, 85, 153-157.	3.0	23
614	Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. <i>Behavioural Brain Research</i> , 2011, 221, 166-171.	2.2	142
615	Glutamatergic drive of the dorsal raphe nucleus. <i>Journal of Chemical Neuroanatomy</i> , 2011, 41, 247-255.	2.1	77
616	Behavioural alteration in chronic pain: Are brain glia involved?. <i>Medical Hypotheses</i> , 2011, 77, 584-588.	1.5	14
617	Stress, glucocorticoids and glutamate release: Effects of antidepressant drugs. <i>Neurochemistry International</i> , 2011, 59, 138-149.	3.8	99
618	Brain-derived neurotrophic factor (BDNF) infusion restored astrocytic plasticity in the hippocampus of a rat model of depression. <i>Neuroscience Letters</i> , 2011, 503, 15-19.	2.1	115
619	Suicidality and epilepsy: A neuropsychobiological perspective. <i>Epilepsy and Behavior</i> , 2011, 22, 77-84.	1.7	45
620	The prefrontal-limbic network in depression: A core pathology of synapse regression. <i>Progress in Neurobiology</i> , 2011, 93, 457-467.	5.7	63
621	The role of Wnt signaling and its interaction with diverse mechanisms of cellular apoptosis in the pathophysiology of bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 11-17.	4.8	18
622	Animal model and neurobiology of suicide. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 818-830.	4.8	46
623	The effects of antidepressants on human brain as detected by imaging studies. Focus on major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1544-1552.	4.8	48
624	Mechanisms of antidepressant action: An integrated dopaminergic perspective. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1532-1543.	4.8	38
625	Induced pluripotent stem cells: A new tool to confront the challenge of neuropsychiatric disorders. <i>Neuropharmacology</i> , 2011, 60, 1355-1363.	4.1	46
626	Biological Alterations in Depression. , 0, , .		3
627	The paradox of electroconvulsive therapy. , 2011, , 321-331.		0

#	ARTICLE	IF	CITATIONS
628	Glucocorticoid Regulation of Astrocytic Fate and Function. PLoS ONE, 2011, 6, e22419.	2.5	35
629	A Single Subanesthetic Dose of Ketamine Relieves Depression-like Behaviors Induced by Neuropathic Pain in Rats. Anesthesiology, 2011, 115, 812-821.	2.5	148
630	Depression Strongly Influences Postconcussion Symptom Reporting Following Mild Traumatic Brain Injury. Journal of Head Trauma Rehabilitation, 2011, 26, 127-137.	1.7	147
631	A morphometric examination of neuronal and glial cell pathology in the orbitofrontal cortex in late-life depression. International Psychogeriatrics, 2011, 23, 132-140.	1.0	45
632	The immunohistochemical examination of GABAergic interneuron markers in the dorsolateral prefrontal cortex of patients with late-life depression. International Psychogeriatrics, 2011, 23, 644-653.	1.0	32
633	A population-based morphometric MRI study in patients with first-episode psychotic bipolar disorder: comparison with geographically matched healthy controls and major depressive disorder subjects. Bipolar Disorders, 2011, 13, 28-40.	1.9	45
634	Examination of glucose transporter ¹ , transforming growth factor ² and neuroglobin immunoreactivity in the orbitofrontal cortex in late-life depression. Psychiatry and Clinical Neurosciences, 2011, 65, 158-164.	1.8	5
635	The GABA _B receptor as a target for antidepressant drug action. British Journal of Pharmacology, 2011, 162, 1-17.	5.4	71
636	Depression and epilepsy: A bidirectional relation?. Epilepsia, 2011, 52, 21-27.	5.1	179
637	Annual Research Review: The promise of stem cell research for neuropsychiatric disorders. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2011, 52, 504-516.	5.2	33
638	Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Molecular Psychiatry, 2011, 16, 634-646.	7.9	313
639	Astrocytic energy metabolism and glutamate formation – relevance for 13C-NMR spectroscopy and importance of cytosolic/mitochondrial trafficking. Magnetic Resonance Imaging, 2011, 29, 1319-1329.	1.8	67
640	Reduced somatostatin in subgenual anterior cingulate cortex in major depression. Neurobiology of Disease, 2011, 42, 116-124.	4.4	156
641	Ventromedial prefrontal spectroscopic abnormalities over the course of depression: A comparison among first episode, remitted recurrent and chronic patients. Journal of Psychiatric Research, 2011, 45, 427-434.	3.1	115
642	The double edged sword of neural plasticity: Increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. Psychoneuroendocrinology, 2011, 36, 339-351.	2.7	121
643	Antistress properties of antidepressant drugs and their clinical implications. , 2011, 132, 39-56.		38
644	Reduction of dorsolateral prefrontal cortex gray matter in late-life depression. Psychiatry Research - Neuroimaging, 2011, 193, 1-6.	1.8	95
645	Cellular pathology within the anterior cingulate cortex of patients with late-life depression: A morphometric study. Psychiatry Research - Neuroimaging, 2011, 194, 184-189.	1.8	23

#	ARTICLE	IF	CITATIONS
646	Towards a neuroimaging biomarker of depression vulnerability. Translational Neuroscience, 2011, 2, .	1.4	4
647	Glia atrophy in the hippocampus of chronic unpredictable stress-induced depression model rats is reversed by electroacupuncture treatment. Journal of Affective Disorders, 2011, 128, 309-313.	4.1	44
648	A morphometric study of glia and neurons in the anterior cingulate cortex in mood disorder. Journal of Affective Disorders, 2011, 133, 328-332.	4.1	103
649	Vascular and extravascular immunoreactivity for intercellular adhesion molecule 1 in the orbitofrontal cortex of subjects with major depression: Age-dependent changes. Journal of Affective Disorders, 2011, 132, 422-431.	4.1	22
650	Cortical thickness and VBM-DARTEL in late-life depression. Journal of Affective Disorders, 2011, 133, 158-164.	4.1	49
651	Graphic patterns of cortical functional connectivity of depressed patients on the basis of EEG measurements. , 2011, 2011, 1419-22.		7
652	Medicalized Psychiatry and the Talking Cure: A Hermeneutic Intervention. Human Studies, 2011, 34, 293-308.	1.0	10
653	Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology, 2011, 216, 75-84.	3.1	176
654	Antidepressant-like effect of artemin in mice: a mechanism for acetyl-l-carnitine activity on depression. Psychopharmacology, 2011, 218, 347-356.	3.1	25
655	Mood Disorders and Obesity: Understanding Inflammation as a Pathophysiological Nexus. NeuroMolecular Medicine, 2011, 13, 93-116.	3.4	135
656	Neuroglial Roots of Neurodegenerative Diseases?. Molecular Neurobiology, 2011, 43, 87-96.	4.0	67
657	Modeling neuronal current MRI signal with human neuron. Magnetic Resonance in Medicine, 2011, 65, 1680-1689.	3.0	23
658	Distinguishing Between Major Depressive Disorder and Obsessive-Compulsive Disorder in Children by Measuring Regional Cortical Thickness. Archives of General Psychiatry, 2011, 68, 527.	12.3	105
659	Paroxetine Rapidly Modulates the Expression of Brain-Derived Neurotrophic Factor mRNA and Protein in a Human Glioblastoma-Astrocytoma Cell Line. Pharmacology, 2011, 87, 5-10.	2.2	31
660	Antidepressants and Neuroinflammation: Can Antidepressants Calm Glial Rage Down?. Mini-Reviews in Medicinal Chemistry, 2011, 11, 555-564.	2.4	46
661	Corticotropin-Releasing Hormone, Glutamate, and Î³-Aminobutyric Acid in Depression. Neuroscientist, 2011, 17, 124-144.	3.5	64
662	Structural Neuroimaging Studies in Major Depressive Disorder. Archives of General Psychiatry, 2011, 68, 675.	12.3	692
663	Protein Binding in Patients With Late-Life Depression. Archives of General Psychiatry, 2011, 68, 1143.	12.3	72

#	ARTICLE	IF	CITATIONS
664	GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. International Journal of Neuropsychopharmacology, 2011, 14, 721-734.	2.1	185
665	Depressive Symptoms and Amygdala Volume in Elderly with Cerebral Small Vessel Disease: The RUN DMC Study. Journal of Aging Research, 2011, 2011, 1-7.	0.9	8
666	Glucocorticoid treatment of astrocytes results in temporally dynamic transcriptome regulation and astrocyte-enriched mRNA changes in vitro. Physiological Genomics, 2012, 44, 1188-1200.	2.3	48
667	Gap Junction Dysfunction in the Prefrontal Cortex Induces Depressive-Like Behaviors in Rats. Neuropsychopharmacology, 2012, 37, 1305-1320.	5.4	202
668	Nine-Year Risk of Depression Diagnosis Increases With Increasing Self-Reported Concussions in Retired Professional Football Players. American Journal of Sports Medicine, 2012, 40, 2206-2212.	4.2	235
669	The role of glia in late-life depression. International Psychogeriatrics, 2012, 24, 1878-1890.	1.0	36
670	Decreased Cortical Thickness in Central Hypoventilation Syndrome. Cerebral Cortex, 2012, 22, 1728-1737.	2.9	13
671	The Role of Oxidative Stress in Depressive Disorders. Current Pharmaceutical Design, 2012, 18, 5890-5899.	1.9	214
672	Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nature Medicine, 2012, 18, 1413-1417.	30.7	640
673	A putative functional role for oligodendrocytes in mood regulation. Translational Psychiatry, 2012, 2, e109-e109.	4.8	150
674	Neurotransmitters and neuropeptides in depression. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 107-136.	1.8	24
675	Association between brain-derived neurotrophic factor <i>V</i>66<i>M</i> and treatment responses to escitalopram in patients with major depressive disorder. Asia-Pacific Psychiatry, 2012, 4, 241-249.	2.2	3
676	Gray Matter Differences Between Healthy and Depressed Adolescents: A Voxel-Based Morphometry Study. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 190-197.	1.3	90
677	Meta-analysis of volumetric abnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder. Psychological Medicine, 2012, 42, 671-681.	4.5	240
678	Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?. Current Neuropharmacology, 2012, 10, 139-158.	2.9	25
679	Neuron density and serotonin receptor binding in prefrontal cortex in suicide. International Journal of Neuropsychopharmacology, 2012, 15, 435-447.	2.1	82
680	The Wnt Pathway in Mood Disorders. Current Neuropharmacology, 2012, 10, 239-253.	2.9	46
681	Low gene expression of bone morphogenetic protein 7 in brainstem astrocytes in major depression. International Journal of Neuropsychopharmacology, 2012, 15, 855-868.	2.1	28

#	ARTICLE	IF	CITATIONS
682	Noradrenergic Dysfunction in Depression and Suicide. <i>Frontiers in Neuroscience</i> , 2012, , 29-64.	0.0	19
683	Impaired adult myelination in the prefrontal cortex of socially isolated mice. <i>Nature Neuroscience</i> , 2012, 15, 1621-1623.	14.8	578
684	Role of prefrontal cortical calcium independent phospholipase A2 in antidepressant-like effect of maprotiline. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1087-1098.	2.1	15
685	Antiinflammatory Treatment Ameliorates HPA Stress Axis Dysfunction in a Mouse Model of Stress Sensitivity. <i>Endocrinology</i> , 2012, 153, 4830-4837.	2.8	15
686	Serum S100B protein is associated with depressive symptoms in patients with end-stage renal disease. <i>Clinical Biochemistry</i> , 2012, 45, 1573-1577.	1.9	15
687	Magnetic resonance imaging studies in unipolar depression: Systematic review and meta-regression analyses. <i>European Neuropsychopharmacology</i> , 2012, 22, 1-16.	0.7	435
688	Neuropathological abnormalities of astrocytes, GABAergic neurons, and pyramidal neurons in the dorsolateral prefrontal cortices of patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2012, 22, 330-338.	0.7	88
689	Prefrontal cortical thickness in depressed patients with high-risk for suicidal behavior. <i>Journal of Psychiatric Research</i> , 2012, 46, 1449-1455.	3.1	154
690	Voxelwise meta-analysis of gray matter reduction in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 11-16.	4.8	206
691	Pathophysiology of Mood Disorders in Temporal Lobe Epilepsy. <i>Revista Brasileira De Psiquiatria</i> , 2012, 34, 233-259.	1.7	36
692	Towards a glutamate hypothesis of depression. <i>Neuropharmacology</i> , 2012, 62, 63-77.	4.1	831
693	The GABA system in anxiety and depression and its therapeutic potential. <i>Neuropharmacology</i> , 2012, 62, 42-53.	4.1	453
694	Cannabinoids and emotionality: a neuroanatomical perspective. <i>Neuroscience</i> , 2012, 204, 134-144.	2.3	71
695	The neurobiology of depression in later-life: Clinical, neuropsychological, neuroimaging and pathophysiological features. <i>Progress in Neurobiology</i> , 2012, 98, 99-143.	5.7	234
696	Depression and epilepsy: Epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. <i>Epilepsy and Behavior</i> , 2012, 24, 156-168.	1.7	238
697	Synaptic Dysfunction in Depression: Potential Therapeutic Targets. <i>Science</i> , 2012, 338, 68-72.	12.6	1,151
698	Melatonin modulates cytoskeletal organization in the rat brain hippocampus. <i>Neuroscience Letters</i> , 2012, 511, 47-51.	2.1	17
699	Region-specific glutamate changes in patients with unipolar depression. <i>Journal of Psychiatric Research</i> , 2012, 46, 1059-1065.	3.1	43

#	ARTICLE	IF	CITATIONS
700	Blockade of Astrocytic Glutamate Uptake in the Prefrontal Cortex Induces Anhedonia. <i>Neuropsychopharmacology</i> , 2012, 37, 2467-2475.	5.4	118
701	Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?. <i>Lancet Neurology</i> , The, 2012, 11, 1093-1102.	10.2	124
702	Fibroblast Growth Factor Receptor 1 α 5-Hydroxytryptamine 1A Heteroreceptor Complexes and Their Enhancement of Hippocampal Plasticity. <i>Biological Psychiatry</i> , 2012, 71, 84-91.	1.3	118
703	Antidepressant Effects of Fibroblast Growth Factor-2 in Behavioral and Cellular Models of Depression. <i>Biological Psychiatry</i> , 2012, 72, 258-265.	1.3	137
704	Effects of fluoxetine on plasticity and apoptosis evoked by chronic stress in rat prefrontal cortex. <i>European Journal of Pharmacology</i> , 2012, 693, 37-44.	3.5	24
705	Divergent effects of lithium and sodium valproate on brain-derived neurotrophic factor (BDNF) production in human astrocytoma cells at therapeutic concentrations. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 39, 17-22.	4.8	21
706	Molecular Imaging of Mood Episodes. <i>Neuromethods</i> , 2012, , 273-303.	0.3	0
707	Novel Insights into Depression and Antidepressants: A Synergy Between Synaptogenesis and Neurogenesis?. <i>Current Topics in Behavioral Neurosciences</i> , 2012, 15, 243-291.	1.7	40
708	A Single-Day Treatment with Mifepristone Is Sufficient to Normalize Chronic Glucocorticoid Induced Suppression of Hippocampal Cell Proliferation. <i>PLoS ONE</i> , 2012, 7, e46224.	2.5	65
709	Antidepressant Acts on Astrocytes Leading to an Increase in the Expression of Neurotrophic/Growth Factors: Differential Regulation of FGF-2 by Noradrenaline. <i>PLoS ONE</i> , 2012, 7, e51197.	2.5	69
710	Expression of Monoamine Transporters, Nitric Oxide Synthase 3, and Neurotrophin Genes in Antidepressant-Stimulated Astrocytes. <i>Frontiers in Psychiatry</i> , 2012, 3, 33.	2.6	17
712	Neuroplasticity and major depression, the role of modern antidepressant drugs. <i>World Journal of Psychiatry</i> , 2012, 2, 49.	2.7	80
713	Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. <i>Synapse</i> , 2012, 66, 435-444.	1.2	29
714	The neurobiology of depression. <i>British Medical Bulletin</i> , 2012, 101, 127-145.	6.9	215
715	Association of attentional shift and reversal learning to functional deficits in geriatric depression. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1172-1179.	2.7	12
716	Gray matter abnormalities in Major Depressive Disorder: A meta-analysis of voxel based morphometry studies. <i>Journal of Affective Disorders</i> , 2012, 138, 9-18.	4.1	638
717	Mapping the depressed brain: A meta-analysis of structural and functional alterations in major depressive disorder. <i>Journal of Affective Disorders</i> , 2012, 140, 142-148.	4.1	281
718	Frontal white matter biochemical abnormalities in first-episode, treatment-naïve patients with major depressive disorder: A proton magnetic resonance spectroscopy study. <i>Journal of Affective Disorders</i> , 2012, 136, 620-626.	4.1	58

#	ARTICLE	IF	CITATIONS
719	A morphometric, immunohistochemical, and in situ hybridization study of the dorsal raphe nucleus in major depression, bipolar disorder, schizophrenia, and suicide. <i>Journal of Affective Disorders</i> , 2012, 137, 125-134.	4.1	58
720	Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients. <i>Journal of Affective Disorders</i> , 2012, 138, 494-502.	4.1	51
721	Pretreatment cerebral metabolic activity correlates with antidepressant efficacy of vagus nerve stimulation in treatment-resistant major depression: A potential marker for response?. <i>Journal of Affective Disorders</i> , 2012, 139, 283-290.	4.1	36
722	Immunohistochemical evidence for impaired nitric oxide signaling of the locus coeruleus in bipolar disorder. <i>Brain Research</i> , 2012, 1459, 91-99.	2.2	17
723	Kynurenines: from the perspective of major psychiatric disorders. <i>FEBS Journal</i> , 2012, 279, 1375-1385.	4.7	193
724	Hippocampal neurometabolite changes in depression treatment: A 1H magnetic resonance spectroscopy study. <i>Psychiatry Research - Neuroimaging</i> , 2012, 201, 206-213.	1.8	19
725	Prefrontal cortical response to emotional faces in individuals with major depressive disorder in remission. <i>Psychiatry Research - Neuroimaging</i> , 2012, 202, 30-37.	1.8	42
726	The role of the kynurenine metabolism in major depression. <i>Journal of Neural Transmission</i> , 2012, 119, 245-251.	2.8	91
727	Neurogenesis and Neural Plasticity. <i>Current Topics in Behavioral Neurosciences</i> , 2013, , .	1.7	7
728	Virginia Woolf and Neuropsychiatry. , 2013, , .		4
729	Astrocytic Adenosine 5â€²-Triphosphate Release Regulates the Proliferation of Neural Stem Cells in the Adult Hippocampus. <i>Stem Cells</i> , 2013, 31, 1633-1643.	3.2	80
730	Neuroplasticity in Depressed Individuals Compared with Healthy Controls. <i>Neuropsychopharmacology</i> , 2013, 38, 2101-2108.	5.4	149
731	The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. <i>Neurology Psychiatry and Brain Research</i> , 2013, 19, 87-101.	2.0	26
732	White matter microstructural abnormalities in bipolar disorder: A whole brain diffusion tensor imaging study. <i>NeuroImage: Clinical</i> , 2013, 2, 558-568.	2.7	75
733	Non-uniformity of cell density and networks in the monkey brain. <i>Scientific Reports</i> , 2013, 3, 2541.	3.3	10
734	Effects of chronic stress on the auditory system and fear learning: an evolutionary approach. <i>Reviews in the Neurosciences</i> , 2013, 24, 227-37.	2.9	10
735	Impaired structural hippocampal plasticity is associated with emotional and memory deficits in the olfactory bulbectomized rat. <i>Neuroscience</i> , 2013, 236, 233-243.	2.3	47
736	Biological substrates underpinning diagnosis of major depression. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1893-1909.	2.1	33

#	ARTICLE	IF	CITATIONS
737	Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience, 2013, 251, 33-50.	2.3	134
738	Environmental and pharmacological modulations of cellular plasticity: Role in the pathophysiology and treatment of depression. Neurobiology of Disease, 2013, 57, 28-37.	4.4	80
739	Activation of Mammalian Target of Rapamycin and Synaptogenesis: Role in the Actions of Rapid-Acting Antidepressants. Biological Psychiatry, 2013, 73, 1189-1198.	1.3	97
740	The Action of Antidepressants on the Glutamate System: Regulation of Glutamate Release and Glutamate Receptors. Biological Psychiatry, 2013, 73, 1180-1188.	1.3	138
741	Altered GABAergic and glutamatergic activity within the rat hippocampus and amygdala in rats subjected to repeated corticosterone administration but not restraint stress. Neuroscience, 2013, 231, 38-48.	2.3	44
742	Was Meduna's Theory Really Wrong?. Revista Brasileira De Psiquiatria, 2013, 35, 94.	1.7	0
743	Tianeptine modulates amygdalar glutamate neurochemistry and synaptic proteins in rats subjected to repeated stress. Experimental Neurology, 2013, 241, 184-193.	4.1	16
744	Cell Number and Neuropil Alterations in Subregions of the Anterior Hippocampus in a Female Monkey Model of Depression. Biological Psychiatry, 2013, 74, 890-897.	1.3	47
745	Glial degeneration as a model of depression. Pharmacological Reports, 2013, 65, 1572-1579.	3.3	26
746	Neuroimaging Approaches to the Understanding of Depression and the Identification of Novel Antidepressants. , 2013, , 343-411.		3
747	Treatment with tianeptine induces antidepressive-like effects and alters the neurotrophin levels, mitochondrial respiratory chain and cycle Krebs enzymes in the brain of maternally deprived adult rats. Metabolic Brain Disease, 2013, 28, 93-105.	2.9	37
748	Identifying brain imaging correlates of clinical response to repetitive transcranial magnetic stimulation (rTMS) in major depression. Brain Stimulation, 2013, 6, 54-61.	1.6	55
749	Coverage of Blood Vessels by Astrocytic Endfeet Is Reduced in Major Depressive Disorder. Biological Psychiatry, 2013, 73, 613-621.	1.3	142
750	Astrocyte-derived ATP modulates depressive-like behaviors. Nature Medicine, 2013, 19, 773-777.	30.7	456
751	From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders. Biological Psychiatry, 2013, 73, 1172-1179.	1.3	201
752	Astrocyte-Neuron Communications. , 2013, , 31-64.		5
753	Context insensitivity during positive and negative emotional expectancy in depression assessed with functional magnetic resonance imaging. Psychiatry Research - Neuroimaging, 2013, 212, 28-35.	1.8	21
754	Research Advances in Geriatric Depression. Focus (American Psychiatric Publishing), 2013, 11, 107-117.	0.8	4

#	ARTICLE	IF	CITATIONS
755	The nucleus accumbens: a target for deep brain stimulation in resistant major depressive disorder. <i>Journal of Molecular Psychiatry</i> , 2013, 1, 17.	2.0	58
756	Decreased NOS1 Expression in the Anterior Cingulate Cortex in Depression. <i>Cerebral Cortex</i> , 2013, 23, 2956-2964.	2.9	59
757	Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, 276-284.	2.4	84
758	Inflammation, Neurotoxins and Psychiatric Disorders. <i>Modern Problems of Pharmacopsychiatry</i> , 2013, 28, 61-74.	2.5	16
759	Paralimbic Cortical Thickness in First-Episode Depression: Evidence for Trait-Related Differences in Mood Regulation. <i>American Journal of Psychiatry</i> , 2013, 170, 1477-1486.	7.2	102
760	The relationship between serum levels of haptoglobin and neopterin and the number of episodes in patients with major depression. <i>Journal of Mood Disorders</i> , 2013, 3, 1.	0.1	23
761	Reflections on worker's compensation in the state of New Jersey. <i>Medicolegal and Bioethics</i> , 2013, , 1.	1.7	0
762	Morphometric analysis of vascular pathology in the orbitofrontal cortex of older subjects with major depression. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 959-970.	2.7	10
763	Captodiamine, a putative antidepressant, enhances hypothalamic BDNF expression in vivo by synergistic 5-HT _{2c} receptor antagonism and sigma-1 receptor agonism. <i>Journal of Psychopharmacology</i> , 2013, 27, 930-939.	4.0	16
764	Cell genesis and dendritic plasticity: a neuroplastic pas de deux in the onset and remission from depression. <i>Molecular Psychiatry</i> , 2013, 18, 748-750.	7.9	31
766	X-Ray Structural Behavior of Some Significant Bioactive Steroids and Their Chemistry in the Crystal Packing and Related Matters. , 2013, , 329-370.		0
767	Mitochondrial dysfunction, oxidative stress, and major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 567.	2.2	104
768	Alterations in Regional Homogeneity of Spontaneous Brain Activity in Late-Life Subthreshold Depression. <i>PLoS ONE</i> , 2013, 8, e53148.	2.5	52
769	Neuroplasticity and the next wave of antidepressant strategies. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 218.	3.7	67
770	Censoring Distances Based on Labeled Cortical Distance Maps in Cortical Morphometry. <i>Frontiers in Neurology</i> , 2013, 4, 155.	2.4	2
771	Acute and chronic glucocorticoid treatments regulate astrocyte-enriched mRNAs in multiple brain regions in vivo. <i>Frontiers in Neuroscience</i> , 2013, 7, 139.	2.8	44
772	Neural Plasticity and Proliferation in the Generation of Antidepressant Effects: Hippocampal Implication. <i>Neural Plasticity</i> , 2013, 2013, 1-21.	2.2	73
773	Neurochemical metabolites in prefrontal cortex in patients with mild/moderate levels in first-episode depression. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1053.	2.2	21

#	ARTICLE	IF	CITATIONS
774	Neurobiological Background of Affective Disorders. , 0, , .		1
775	First-Episode Medication-Naive Major Depressive Disorder Is Associated with Altered Resting Brain Function in the Affective Network. PLoS ONE, 2014, 9, e85241.	2.5	75
776	GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease. Frontiers in Cellular Neuroscience, 2014, 8, 167.	3.7	88
777	Role of Omega-3 Fatty Acids in Brain and Neurological Health with Special Reference to Clinical Depression. , 2014, , 163-179.		3
778	No change in N-acetyl aspartate in first episode of moderate depression after antidepressant treatment: 1H magnetic spectroscopy study of left amygdala and left dorsolateral prefrontal cortex. Neuropsychiatric Disease and Treatment, 2014, 10, 1753.	2.2	3
779	Recent Approaches for Studying the Role of Glia. CNS and Neurological Disorders - Drug Targets, 2014, 13, 52-62.	1.4	1
781	Effects of brief pulse and ultrabrief pulse electroconvulsive stimulation on rodent brain and behaviour in the corticosterone model of depression. International Journal of Neuropsychopharmacology, 2014, 17, 1477-1486.	2.1	19
782	Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Translational Psychiatry, 2014, 4, e389-e389.	4.8	123
783	Regional increases of cortical thickness in untreated, first-episode major depressive disorder. Translational Psychiatry, 2014, 4, e378-e378.	4.8	157
784	Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders. Frontiers in Genetics, 2014, 5, 239.	2.3	21
785	Role of NG2 expressing cells in addiction: a new approach for an old problem. Frontiers in Pharmacology, 2014, 5, 279.	3.5	14
786	Trophic Mechanisms for Exercise-Induced Stress Resilience: Potential Role of Interactions between BDNF and Galanin. Frontiers in Psychiatry, 2014, 5, 90.	2.6	22
787	Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies. , 2014, , 313-341.		0
788	The neural correlates of regulating positive and negative emotions in medication-free major depression. Social Cognitive and Affective Neuroscience, 2014, 9, 628-637.	3.0	78
789	Anxious/Depressed Symptoms are Linked to Right Ventromedial Prefrontal Cortical Thickness Maturation in Healthy Children and Young Adults. Cerebral Cortex, 2014, 24, 2941-2950.	2.9	149
790	Brain grey matter abnormalities in medication-free patients with major depressive disorder: a meta-analysis. Psychological Medicine, 2014, 44, 2927-2937.	4.5	159
791	GATA1: a novel target for gene therapy in major depressive disorder. Animal Cells and Systems, 2014, 18, 291-295.	2.2	2
792	Hippocampal Neurogenesis and Antidepressive Therapy: Shocking Relations. Neural Plasticity, 2014, 2014, 1-14.	2.2	64

#	ARTICLE	IF	CITATIONS
793	Hypothalamus-Anchored Resting Brain Network Changes before and after Sertraline Treatment in Major Depression. BioMed Research International, 2014, 2014, 1-7.	1.9	37
794	Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk. Psychological Medicine, 2014, 44, 3491-3501.	4.5	37
795	Cellular Morphometry in Late-Life Depression: A Review of Postmortem Studies. American Journal of Geriatric Psychiatry, 2014, 22, 122-132.	1.2	11
796	NEUROBIOLOGY OF STRESS, DEPRESSION, AND RAPID ACTING ANTIDEPRESSANTS: REMODELING SYNAPTIC CONNECTIONS. Depression and Anxiety, 2014, 31, 291-296.	4.1	162
797	Synaptic regulation of affective behaviors; role of BDNF. Neuropharmacology, 2014, 76, 684-695.	4.1	89
798	Reducing the neural search space for hominid cognition: What distinguishes human and great ape brains from those of small apes?. Psychonomic Bulletin and Review, 2014, 21, 590-619.	2.8	14
799	REDD1 is essential for stress-induced synaptic loss and depressive behavior. Nature Medicine, 2014, 20, 531-535.	30.7	226
800	Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?). Neurotherapeutics, 2014, 11, 358-372.	4.4	82
801	Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. Journal of Neural Transmission, 2014, 121, 907-924.	2.8	115
802	Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 304-313.	4.8	184
803	Glial abnormalities in substance use disorders and depression: Does shared glutamatergic dysfunction contribute to comorbidity?. World Journal of Biological Psychiatry, 2014, 15, 2-16.	2.6	26
804	Is depression associated with an increased risk of treatment-resistant epilepsy? Research strategies to investigate this question. Epilepsy and Behavior, 2014, 38, 3-7.	1.7	52
805	Amitriptyline up-regulates connexin43 gap junction in rat cultured cortical astrocytes via activation of the p38 and c-Jun/Fos/AP-1 signalling pathway. British Journal of Pharmacology, 2014, 171, 2854-2867.	5.4	60
806	Moonlighting Proteins and Protein-Protein Interactions as Neurotherapeutic Targets in the G Protein-Coupled Receptor Field. Neuropsychopharmacology, 2014, 39, 131-155.	5.4	101
807	Pyramidal neurons of the prefrontal cortex in post-stroke, vascular and other ageing-related dementias. Brain, 2014, 137, 2509-2521.	7.6	46
808	FADD adaptor and PEA-15/ERK1/2 partners in major depression and schizophrenia postmortem brains: Basal contents and effects of psychotropic treatments. Neuroscience, 2014, 277, 541-551.	2.3	31
809	Synaptic Stress and Pathogenesis of Neuropsychiatric Disorders. , 2014, , .		2
810	Similarities of biochemical abnormalities between major depressive disorder and bipolar depression: A proton magnetic resonance spectroscopy study. Journal of Affective Disorders, 2014, 168, 380-386.	4.1	69

#	ARTICLE	IF	CITATIONS
811	Toward an Understanding of the Neural Circuitry of Major Depressive Disorder Through the Clinical Response to Deep Brain Stimulation of Different Anatomical Targets. <i>Current Behavioral Neuroscience Reports</i> , 2014, 1, 55-63.	1.3	20
812	Cortical thickness in youth with major depressive disorder. <i>BMC Psychiatry</i> , 2014, 14, 83.	2.6	80
813	Dissociation of glutamate and cortical thickness is restricted to regions subserving trait but not state markers in major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 169, 91-100.	4.1	35
814	Ketamine reverses stress-induced depression-like behavior and increased GABA levels in the anterior cingulate: An 11.7T 1H-MRS study in rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 51, 9-15.	4.8	58
815	Gender influence on schizophreniaâ€”relevant abnormalities in a cuprizone demyelination model. <i>Glia</i> , 2014, 62, 1629-1644.	4.9	17
816	Nitric oxide signaling in the development and evolution of language and cognitive circuits. <i>Neuroscience Research</i> , 2014, 86, 77-87.	1.9	5
817	Immunology of Major Depression. <i>NeuroImmunoModulation</i> , 2014, 21, 123-130.	1.8	136
818	Alterations in Gene Expression in Depression. <i>Advances in Protein Chemistry and Structural Biology</i> , 2015, 101, 97-124.	2.3	3
820	Neural markers of familial risk for depression: An investigation of cortical thickness abnormalities in healthy adolescent daughters of mothers with recurrent depression.. <i>Journal of Abnormal Psychology</i> , 2015, 124, 476-485.	1.9	39
822	Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes. <i>Journal of Neuroinflammation</i> , 2015, 12, 225.	7.2	23
823	Original article Sertraline and curcumin prevent stress-induced morphological changes of dendrites and neurons in the medial prefrontal cortex of rats. <i>Folia Neuropathologica</i> , 2015, 1, 69-79.	1.2	23
824	Glia in the cytokine-mediated onset of depression: fine tuning the immune response. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 268.	3.7	58
825	A New Outlook on Mental Illnesses: Glial Involvement Beyond the Glue. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 468.	3.7	49
826	Altered Synchronizations among Neural Networks in Geriatric Depression. <i>BioMed Research International</i> , 2015, 2015, 1-12.	1.9	12
827	Neural, cognitive, and neuroimaging markers of the suicidal brain. <i>Reports in Medical Imaging</i> , 2015, , 71.	0.8	4
828	Hippocampal Morphology in a Rat Model of Depression: The Effects of Physical Activity. <i>Open Neuroimaging Journal</i> , 2015, 9, 1-6.	0.2	17
829	The Effects of Psychotherapy on Brain Function â€” Major Depressive Disorder. , 0, , .		2
830	Astrocyte and Microglial Control of Glutamatergic Signalling: A Primer on Understanding the Disruptive Role of Chronic Stress. <i>Journal of Neuroendocrinology</i> , 2015, 27, 498-506.	2.6	36

#	ARTICLE	IF	CITATIONS
831	Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease. Cellular and Molecular Life Sciences, 2015, 72, 3489-3506.	5.4	130
832	Long-term imipramine treatment increases N-methyl-d-aspartate receptor activity and expression via epigenetic mechanisms. European Journal of Pharmacology, 2015, 752, 69-77.	3.5	24
833	Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies. Journal of Psychiatric Research, 2015, 68, 316-328.	3.1	167
834	Forkhead box O transcription factors as possible mediators in the development of major depression. Neuropharmacology, 2015, 99, 527-537.	4.1	50
835	Chronically Restricted or Disrupted Sleep as a Causal Factor in the Development of Depression. Current Topics in Behavioral Neurosciences, 2015, 25, 459-481.	1.7	79
836	Effect of antidepressant drugs on the vmPFC-limbic circuitry. Neuropharmacology, 2015, 92, 116-124.	4.1	21
837	Lurasidone Exerts Antidepressant Properties in the Chronic Mild Stress Model through the Regulation of Synaptic and Neuroplastic Mechanisms in the Rat Prefrontal Cortex. International Journal of Neuropsychopharmacology, 2015, 18, .	2.1	48
838	Oligodendrocyte morphometry and expression of myelin â€œ Related mRNA in ventral prefrontal white matter in major depressive disorder. Journal of Psychiatric Research, 2015, 65, 53-62.	3.1	76
839	Cortico-limbic network abnormalities in individuals with current and past major depressive disorder. Journal of Affective Disorders, 2015, 173, 45-52.	4.1	42
840	Different stress-related gene expression in depression and suicide. Journal of Psychiatric Research, 2015, 68, 176-185.	3.1	36
841	Chronic stress and brain plasticity: Mechanisms underlying adaptive and maladaptive changes and implications for stress-related CNS disorders. Neuroscience and Biobehavioral Reviews, 2015, 58, 79-91.	6.1	177
842	Altered expression of neuroplasticity-related genes in the brain of depressed suicides. Neuroscience, 2015, 299, 1-17.	2.3	61
843	Psychiatric Disease and Post-Acute Traumatic Brain Injury. Journal of Neurotrauma, 2015, 32, 1911-1925.	3.4	83
844	Indirect evidence of selective glial involvement in glutamate-based mechanisms of mood regulation in depression: Meta-analysis of absolute prefrontal neuro-metabolic concentrations. European Neuropsychopharmacology, 2015, 25, 1109-1117.	0.7	123
845	In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature. Annals of the New York Academy of Sciences, 2015, 1344, 50-65.	3.8	80
846	Functional and Structural Remodeling of Glutamate Synapses in Prefrontal and Frontal Cortex Induced by Behavioral Stress. Frontiers in Psychiatry, 2015, 6, 60.	2.6	65
847	Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Design, Development and Therapy, 2015, 9, 603.	4.3	117
848	A Computational Model of Major Depression: the Role of Glutamate Dysfunction on Cingulo-Frontal Network Dynamics. Cerebral Cortex, 2017, 27, bhv249.	2.9	40

#	ARTICLE	IF	CITATIONS
849	Neuroanatomical correlates of negative emotionality-related traits: A systematic review and meta-analysis. <i>Neuropsychologia</i> , 2015, 77, 97-118.	1.6	70
851	The relevance of neuropsychiatric symptoms and cognitive problems in new-onset epilepsy â€” Current knowledge and understanding. <i>Epilepsy and Behavior</i> , 2015, 51, 199-209.	1.7	45
852	A Prospective, Longitudinal Study of the Effect of Remission on Cortical Thickness and Hippocampal Volume in Patients with Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv037-pyv037.	2.1	107
853	Chronic mild stress and imipramine treatment elicit opposite changes in behavior and in gene expression in the mouse prefrontal cortex. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 135, 227-236.	2.9	27
854	Neuropathology of Depression in Alzheimer's Disease: Current Knowledge and the Potential for New Treatments. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 27-41.	2.6	47
855	Repeated restraint stress-induced atrophy of glutamatergic pyramidal neurons and decreases in glutamatergic efflux in the rat amygdala are prevented by the antidepressant agomelatine. <i>Neuroscience</i> , 2015, 284, 430-443.	2.3	35
856	Disrupted structural connectivity network in treatment-naïve depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 56, 18-26.	4.8	58
857	BICC1 Expression is Elevated in Depressed Subjects and Contributes to Depressive Behavior in Rodents. <i>Neuropsychopharmacology</i> , 2015, 40, 711-718.	5.4	18
858	Stress, the Autonomic Nervous System, and the Immune-kynurenine Pathway in the Etiology of Depression. <i>Current Neuropharmacology</i> , 2016, 14, 665-673.	2.9	183
859	Altered ERK1/2 Signaling in the Brain of Learned Helpless Rats: Relevance in Vulnerability to Developing Stress-Induced Depression. <i>Neural Plasticity</i> , 2016, 2016, 1-18.	2.2	32
860	Distinction of Neurons, Glia and Endothelial Cells in the Cerebral Cortex: An Algorithm Based on Cytological Features. <i>Frontiers in Neuroanatomy</i> , 2016, 10, 107.	1.7	161
861	Depression as a Glial-Based Synaptic Dysfunction. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 521.	3.7	134
862	Fluoxetine Requires the Endfeet Protein Aquaporin-4 to Enhance Plasticity of Astrocyte Processes. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 8.	3.7	55
863	Erythropoietin Pathway: A Potential Target for the Treatment of Depression. <i>International Journal of Molecular Sciences</i> , 2016, 17, 677.	4.1	38
864	Dendritic Spines in Depression: What We Learned from Animal Models. <i>Neural Plasticity</i> , 2016, 2016, 1-26.	2.2	293
865	What can animal models tell us about depressive disorders?. , 2016, , 35-86.		13
866	Proton spectroscopy study of the dorsolateral prefrontal cortex in youth with familial depression. <i>Psychiatry and Clinical Neurosciences</i> , 2016, 70, 269-277.	1.8	20
867	A lack of Î±1A-adrenergic receptor-mediated antidepressant-like effects of S-(+)-niguldipine and B8805-033 in the forced swim test. <i>Behavioural Pharmacology</i> , 2016, 27, 397-401.	1.7	1

#	ARTICLE	IF	CITATIONS
868	Assessment of abnormal brain structures and networks in major depressive disorder using morphometric and connectome analyses. <i>Journal of Affective Disorders</i> , 2016, 205, 103-111.	4.1	40
869	Prefrontal changes in the glutamate-glutamine cycle and neuronal/glial glutamate transporters in depression with and without suicide. <i>Journal of Psychiatric Research</i> , 2016, 82, 8-15.	3.1	66
870	Computational meta-analysis of statistical parametric maps in major depression. <i>Human Brain Mapping</i> , 2016, 37, 1393-1404.	3.6	158
871	Why are there lasting effects from exposure to stress during development? An analysis of current models of early stress. <i>Physiology and Behavior</i> , 2016, 164, 164-181.	2.1	21
872	An animal model of detrusor overactivity induced by depression. <i>Journal of Pharmacological and Toxicological Methods</i> , 2016, 80, 19-25.	0.7	4
873	Localized or diffuse: the link between prefrontal cortex volume and cognitive reappraisal. <i>Social Cognitive and Affective Neuroscience</i> , 2016, 11, 1317-1325.	3.0	16
874	The dose makes the poison: from glutamate-mediated neurogenesis to neuronal atrophy and depression. <i>Reviews in the Neurosciences</i> , 2016, 27, 599-622.	2.9	36
875	EphB2 in the Medial Prefrontal Cortex Regulates Vulnerability to Stress. <i>Neuropsychopharmacology</i> , 2016, 41, 2541-2556.	5.4	44
876	Synaptic alterations associated with depression and schizophrenia: potential as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1195-1207.	3.4	33
877	Putative Cell Adhesion Membrane Protein Vstm5 Regulates Neuronal Morphology and Migration in the Central Nervous System. <i>Journal of Neuroscience</i> , 2016, 36, 10181-10197.	3.6	13
878	Biophysical modeling of high field diffusion MRI demonstrates micro-structural aberration in chronic mild stress rat brain. <i>NeuroImage</i> , 2016, 142, 421-430.	4.2	48
879	Differential effect of lithium on cell number in the hippocampus and prefrontal cortex in adult mice: a stereological study. <i>Bipolar Disorders</i> , 2016, 18, 41-51.	1.9	35
880	Region-specific alterations of A-to-I RNA editing of serotonin 2c receptor in the cortex of suicides with major depression. <i>Translational Psychiatry</i> , 2016, 6, e878-e878.	4.8	43
881	Repression of Astrocytic Connexins in Cortical and Subcortical Brain Regions and Prefrontal Enrichment of H3K9me3 in Depression and Suicide. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, pyw071.	2.1	63
882	Expression of p21-activated kinases 1 and 3 is altered in the brain of subjects with depression. <i>Neuroscience</i> , 2016, 333, 331-344.	2.3	20
883	Inverse changes in L1 retrotransposons between blood and brain in major depressive disorder. <i>Scientific Reports</i> , 2016, 6, 37530.	3.3	29
884	Astroglia, Glutamatergic Transmission and Psychiatric Diseases. <i>Advances in Neurobiology</i> , 2016, 13, 307-326.	1.8	16
885	What is the impact of child abuse on gray matter abnormalities in individuals with major depressive disorder: a case control study. <i>BMC Psychiatry</i> , 2016, 16, 397.	2.6	16

#	ARTICLE	IF	CITATIONS
886	The effect of nitrazepam on depression and curiosity in behavioral tests in mice: The role of potassium channels. <i>European Journal of Pharmacology</i> , 2016, 791, 369-376.	3.5	16
887	Label-free distinguishing between neurons and glial cells based on two-photon excited fluorescence signal of neuron perinuclear granules. <i>Laser Physics Letters</i> , 2016, 13, 085603.	1.4	4
888	Acute agmatine administration, similar to ketamine, reverses depressive-like behavior induced by chronic unpredictable stress in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 150-151, 108-114.	2.9	41
889	High-field magnetic resonance imaging of structural alterations in first-episode, drug-naïve patients with major depressive disorder. <i>Translational Psychiatry</i> , 2016, 6, e942-e942.	4.8	47
890	Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 31, 173-198.	1.7	99
891	Regional cortical thinning of the orbitofrontal cortex in medication-naïve female patients with major depressive disorder is not associated with MAOA-uVNTR polymorphism. <i>Annals of General Psychiatry</i> , 2016, 15, 26.	2.7	8
892	Depressive symptom severity is associated with increased cortical thickness in older adults. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 325-333.	2.7	33
893	Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration. <i>Psychopharmacology</i> , 2016, 233, 2955-2971.	3.1	24
894	Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 71, 27-38.	4.8	42
895	Electroconvulsive therapy and structural neuroplasticity in neocortical, limbic and paralimbic cortex. <i>Translational Psychiatry</i> , 2016, 6, e832-e832.	4.8	91
896	Variations in myo-inositol in fronto-limbic regions and clinical response to electroconvulsive therapy in major depression. <i>Journal of Psychiatric Research</i> , 2016, 80, 45-51.	3.1	16
897	A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex. <i>European Journal of Pharmacology</i> , 2016, 786, 29-35.	3.5	27
898	Pre-treatment letter fluency performance predicts antidepressant response to transcranial direct current stimulation. <i>Journal of Affective Disorders</i> , 2016, 203, 130-135.	4.1	19
899	Pathogenesis of depression: Insights from human and rodent studies. <i>Neuroscience</i> , 2016, 321, 138-162.	2.3	383
900	Adult Neurogenesis and Psychiatric Disorders. <i>Cold Spring Harbor Perspectives in Biology</i> , 2016, 8, a019026.	5.5	146
901	Neuropathological relationship between major depression and dementia: A hypothetical model and review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 67, 51-57.	4.8	89
902	Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder. <i>Biological Psychiatry</i> , 2016, 80, 439-447.	1.3	58
903	Depression-Related Increases and Decreases in Appetite: Dissociable Patterns of Aberrant Activity in Reward and Interoceptive Neurocircuitry. <i>American Journal of Psychiatry</i> , 2016, 173, 418-428.	7.2	147

#	ARTICLE	IF	CITATIONS
904	Imbalanced spontaneous brain activity in orbitofrontal-insular circuits in individuals with cognitive vulnerability to depression. <i>Journal of Affective Disorders</i> , 2016, 198, 56-63.	4.1	27
905	Physical activity and exercise attenuate neuroinflammation in neurological diseases. <i>Brain Research Bulletin</i> , 2016, 125, 19-29.	3.0	84
906	Amitriptyline induces brain-derived neurotrophic factor (BDNF) mRNA expression through ERK-dependent modulation of multiple BDNF mRNA variants in primary cultured rat cortical astrocytes and microglia. <i>Brain Research</i> , 2016, 1634, 57-67.	2.2	53
907	Reduced GABA neuron density in auditory cerebral cortex of subjects with major depressive disorder. <i>Journal of Chemical Neuroanatomy</i> , 2016, 76, 108-121.	2.1	28
908	Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder. <i>Neuroscience</i> , 2016, 316, 209-220.	2.3	180
909	Translational potential of astrocytes in brain disorders. <i>Progress in Neurobiology</i> , 2016, 144, 188-205.	5.7	89
910	Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. <i>Molecular Psychiatry</i> , 2017, 22, 900-909.	7.9	852
911	How do antidepressants influence the BOLD signal in the developing brain?. <i>Developmental Cognitive Neuroscience</i> , 2017, 25, 45-57.	4.0	12
912	Rapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms. <i>Chronic Stress</i> , 2017, 1, 247054701769731.	3.4	52
913	Cortical thickness is not associated with current depression in a clinical treatment study. <i>Human Brain Mapping</i> , 2017, 38, 4370-4385.	3.6	17
914	Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives. <i>Biological Psychiatry</i> , 2017, 82, 549-559.	1.3	238
915	Orbitofrontal and caudate volumes in cannabis users: a multi-site mega-analysis comparing dependent versus non-dependent users. <i>Psychopharmacology</i> , 2017, 234, 1985-1995.	3.1	32
916	A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia. <i>Experimental Physiology</i> , 2017, 102, 587-597.	2.0	3
917	An astroglial basis of major depressive disorder? An overview. <i>Glia</i> , 2017, 65, 1227-1250.	4.9	156
918	Cacna1c in the Prefrontal Cortex Regulates Depression-Related Behaviors via REDD1. <i>Neuropsychopharmacology</i> , 2017, 42, 2032-2042.	5.4	44
919	Inflammation-Associated Depression: Evidence, Mechanisms and Implications. <i>Current Topics in Behavioral Neurosciences</i> , 2017, , .	1.7	24
920	Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control. <i>NeuroImage</i> , 2017, 147, 198-203.	4.2	22
921	Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence. <i>Psychopharmacology</i> , 2017, 234, 631-645.	3.1	16

#	ARTICLE	IF	CITATIONS
922	Magnetic resonance microdynamic imaging reveals distinct tissue microenvironments. <i>NeuroImage</i> , 2017, 163, 183-196.	4.2	52
923	iTRAQ-Based Proteomics Suggests Ephb6 as a Potential Regulator of the ERK Pathway in the Prefrontal Cortex of Chronic Social Defeat Stress Model Mice. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1700115.	1.6	5
924	Major depressive disorder and anxiety disorders from the glial perspective: Etiological mechanisms, intervention and monitoring. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 83, 474-488.	6.1	40
925	Possible target-related proteins of stress-resistant rats suggested by label-free proteomic analysis. <i>RSC Advances</i> , 2017, 7, 40957-40964.	3.6	6
926	Role of Dopamine D2 Receptor in Stress-Induced Myelin Loss. <i>Scientific Reports</i> , 2017, 7, 11654.	3.3	19
927	Brain grey matter volume alterations associated with antidepressant response in major depressive disorder. <i>Scientific Reports</i> , 2017, 7, 10464.	3.3	26
928	Conjoint and dissociated structural and functional abnormalities in first-episode drug-naïve patients with major depressive disorder: a multimodal meta-analysis. <i>Scientific Reports</i> , 2017, 7, 10401.	3.3	46
929	Length of axons expressing the serotonin transporter in orbitofrontal cortex is lower with age in depression. <i>Neuroscience</i> , 2017, 359, 30-39.	2.3	21
930	Lateralized hippocampal volume increase following high-frequency left prefrontal repetitive transcranial magnetic stimulation in patients with major depression. <i>Psychiatry and Clinical Neurosciences</i> , 2017, 71, 747-758.	1.8	33
931	Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 80, 555-572.	6.1	31
932	Association between change in brain gray matter volume, cognition, and depression severity: Pre- and post- antidepressant pharmacotherapy for late-life depression. <i>Journal of Psychiatric Research</i> , 2017, 95, 129-134.	3.1	16
934	Neuropathology of suicide: recent findings and future directions. <i>Molecular Psychiatry</i> , 2017, 22, 1395-1412.	7.9	111
935	Can Neurochemical Changes of Mood Disorders Explain the Increase Risk of Epilepsy or its Worse Seizure Control?. <i>Neurochemical Research</i> , 2017, 42, 2071-2076.	3.3	18
936	HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. <i>Behavioural Brain Research</i> , 2017, 333, 54-66.	2.2	18
937	Local gyrification index in patients with major depressive disorder and its association with tryptophan hydroxylase-2 (TPH2) polymorphism. <i>Human Brain Mapping</i> , 2017, 38, 1299-1310.	3.6	35
938	The neuroanatomy of depression: A review. <i>Clinical Anatomy</i> , 2017, 30, 44-49.	2.7	34
939	Chronic stress affects the number of GABAergic neurons in the orbitofrontal cortex of rats. <i>Behavioural Brain Research</i> , 2017, 316, 104-114.	2.2	35
940	Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. <i>Neuropsychopharmacology</i> , 2017, 42, 193-215.	5.4	343

#	ARTICLE	IF	CITATIONS
941	Autoimmune Aspects of Neurodegenerative and Psychiatric Diseases: A Template for Innovative Therapy. <i>Frontiers in Psychiatry</i> , 2017, 8, 46.	2.6	21
942	Alternations of White Matter Structural Networks in First Episode Untreated Major Depressive Disorder with Short Duration. <i>Frontiers in Psychiatry</i> , 2017, 8, 205.	2.6	14
943	Therapeutic Effect of Astroglia-like Mesenchymal Stem Cells Expressing Glutamate Transporter in a Genetic Rat Model of Depression. <i>Theranostics</i> , 2017, 7, 2690-2703.	10.0	45
944	Mediators of Glucocorticoid-Regulated Adaptive Plasticity. , 0, , .		2
945	Novel rapid-acting antidepressants: molecular and cellular signaling mechanisms. <i>Neuronal Signaling</i> , 2017, 1, .	3.2	10
946	Correlation and Comparison of Cortical and Hippocampal Neural Progenitor Morphology and Differentiation through the Use of Micro- and Nano-Topographies. <i>Journal of Functional Biomaterials</i> , 2017, 8, 35.	4.4	5
947	Involvement of Astrocytes in Alzheimer's Disease from a Neuroinflammatory and Oxidative Stress Perspective. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 427.	2.9	377
948	From Engrams to Pathologies of the Brain. <i>Frontiers in Neural Circuits</i> , 2017, 11, 23.	2.8	32
949	A Resting-State Brain Functional Network Study in MDD Based on Minimum Spanning Tree Analysis and the Hierarchical Clustering. <i>Complexity</i> , 2017, 2017, 1-11.	1.6	51
951	Opposite Molecular Signatures of Depression in Men and Women. <i>Biological Psychiatry</i> , 2018, 84, 18-27.	1.3	205
952	The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling. <i>Neuropharmacology</i> , 2018, 135, 22-33.	4.1	138
953	Convergent Mechanisms Underlying Rapid Antidepressant Action. <i>CNS Drugs</i> , 2018, 32, 197-227.	5.9	127
954	Evidence for additionally increased apoptosis in the peripheral blood mononuclear cells of major depressive patients with a high risk for suicide. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 388-396.	1.7	11
955	OBscure but not OBsolete: Perturbations of the frontal cortex in common between rodent olfactory bulbectomy model and major depression. <i>Journal of Chemical Neuroanatomy</i> , 2018, 91, 63-100.	2.1	13
956	Serotonergic Modulation of Cognition in Prefrontal Cortical Circuits in Major Depression. , 2018, , 27-46.		4
957	The use of diffusional kurtosis imaging and neurite orientation dispersion and density imaging of the brain in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2018, 98, 22-29.	3.1	17
958	Diagnosis of Major Depressive Disorders: Clinical and Biological Perspectives. , 2018, , 53-68.		1
959	Prefrontal alterations in GABAergic and glutamatergic gene expression in relation to depression and suicide. <i>Journal of Psychiatric Research</i> , 2018, 102, 261-274.	3.1	73

#	ARTICLE	IF	CITATIONS
960	Association of Brain Cortical Changes With Relapse in Patients With Major Depressive Disorder. JAMA Psychiatry, 2018, 75, 484.	11.0	60
961	Neurobiology of depression: A neurodevelopmental approach. World Journal of Biological Psychiatry, 2018, 19, 349-359.	2.6	59
962	Human astrocytes in the diseased brain. Brain Research Bulletin, 2018, 136, 139-156.	3.0	183
963	Astrocytes in Memory Function: Pioneering Findings and Future Directions. Neuroscience, 2018, 370, 14-26.	2.3	60
964	Neurodevelopmental theory of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 267-272.	4.8	44
965	Alterations in the steroid biosynthetic pathways in the human prefrontal cortex in mood disorders: A post-mortem study. Brain Pathology, 2018, 28, 536-547.	4.1	22
966	Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 87, 126-146.	4.8	100
967	Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities. Annual Review of Pharmacology and Toxicology, 2018, 58, 411-428.	9.4	82
968	Gap junction channels as potential targets for the treatment of major depressive disorder. Psychopharmacology, 2018, 235, 1-12.	3.1	41
969	Epigenetic profiles associated with major depression in the human brain. Psychiatry Research, 2018, 260, 439-442.	3.3	15
970	Epigenetic mechanisms of major depression: Targeting neuronal plasticity. Psychiatry and Clinical Neurosciences, 2018, 72, 212-227.	1.8	118
971	CK2 regulates 5-HT4 receptor signaling and modulates depressive-like behavior. Molecular Psychiatry, 2018, 23, 872-882.	7.9	23
972	Chronic Unpredictable Stress Reduces Immunostaining for Connexins 43 and 30 and Myelin Basic Protein in the Rat Prelimbic and Orbitofrontal Cortices. Chronic Stress, 2018, 2, 247054701881418.	3.4	27
973	S100B Levels in Patients with Type 2 Diabetes Mellitus and Co-Occurring Depressive Symptoms. Depression Research and Treatment, 2018, 2018, 1-8.	1.3	4
974	Magnetic seizure therapy reduces suicidal ideation and produces neuroplasticity in treatment-resistant depression. Translational Psychiatry, 2018, 8, 253.	4.8	49
975	Subgenual Cingulate Deep Brain Stimulation for Treatment-Resistant Depression. , 2018, , 1099-1118.		2
976	Decreased Neuron Density and Increased Glia Density in the Ventromedial Prefrontal Cortex (Brodmann Area 25) in Williams Syndrome. Brain Sciences, 2018, 8, 209.	2.3	9
977	Leptin in depression: a potential therapeutic target. Cell Death and Disease, 2018, 9, 1096.	6.3	58

#	ARTICLE	IF	CITATIONS
978	Involvement of Innate and Adaptive Immune Systems Alterations in the Pathophysiology and Treatment of Depression. <i>Frontiers in Neuroscience</i> , 2018, 12, 547.	2.8	71
979	Menin Deficiency Leads to Depressive-like Behaviors in Mice by Modulating Astrocyte-Mediated Neuroinflammation. <i>Neuron</i> , 2018, 100, 551-563.e7.	8.1	144
980	Association between resting-state brain functional connectivity and cortisol levels in unmedicated major depressive disorder. <i>Journal of Psychiatric Research</i> , 2018, 105, 55-62.	3.1	12
981	Monoaminergic and aminoacidergic receptors are involved in the antidepressant-like effect of ginsenoside Rb1 in mouse hippocampus (CA3) and prefrontal cortex. <i>Brain Research</i> , 2018, 1699, 44-53.	2.2	36
982	Reduced GABAergic cortical inhibition in aging and depression. <i>Neuropsychopharmacology</i> , 2018, 43, 2277-2284.	5.4	34
983	Clinical Trials of Anti-Inflammatory Treatments of Major Depression. , 2018, , 489-507.		2
984	Orphan receptor GPR158 controls stress-induced depression. <i>ELife</i> , 2018, 7, .	6.0	56
985	Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E. <i>Nature Communications</i> , 2018, 9, 2459.	12.8	65
986	Gunn rats with glial activation in the hippocampus show prolonged immobility time in the forced swimming test and tail suspension test. <i>Brain and Behavior</i> , 2018, 8, e01028.	2.2	26
987	Subanesthetic ketamine reverses neuronal and astroglial metabolic activity deficits in a social defeat model of depression. <i>Journal of Neurochemistry</i> , 2018, 146, 722-734.	3.9	24
988	Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. <i>Psychopharmacology</i> , 2018, 235, 2195-2220.	3.1	184
989	Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. <i>Neuropsychopharmacology</i> , 2018, 43, 2221-2230.	5.4	61
990	Glucocorticoid receptor activation induces decrease of hippocampal astrocyte number in rats. <i>Psychopharmacology</i> , 2018, 235, 2529-2540.	3.1	19
991	Effects of Monoamines and Antidepressants on Astrocyte Physiology: Implications for Monoamine Hypothesis of Depression. <i>Journal of Experimental Neuroscience</i> , 2018, 12, 117906951878914.	2.3	44
992	Reduced Synapse and Axon Numbers in the Prefrontal Cortex of Rats Subjected to a Chronic Stress Model for Depression. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 24.	3.7	72
993	Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 421.	2.9	151
994	Clinical Findings Documenting Cellular and Molecular Abnormalities of Glia in Depressive Disorders. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 56.	2.9	44
995	IDO and TDO as a potential therapeutic target in different types of depression. <i>Metabolic Brain Disease</i> , 2018, 33, 1787-1800.	2.9	52

#	ARTICLE	IF	CITATIONS
996	Inference of cell type content from human brain transcriptomic datasets illuminates the effects of age, manner of death, dissection, and psychiatric diagnosis. PLoS ONE, 2018, 13, e0200003.	2.5	65
997	Is poststroke depression the same as major depression?. Journal of Psychiatry and Neuroscience, 2018, 43, 76-77.	2.4	9
998	Adult neurogenesis and its role in brain injury and psychiatric diseases. Journal of Neurochemistry, 2018, 147, 584-594.	3.9	42
999	Abnormal hippocampal neurogenesis in Parkinson's disease: relevance to a new therapeutic target for depression with Parkinson's disease. Archives of Pharmacal Research, 2018, 41, 943-954.	6.3	59
1000	Low on energy? An energy supply-demand perspective on stress and depression. Neuroscience and Biobehavioral Reviews, 2018, 94, 248-270.	6.1	33
1001	Differential microstructural alterations in rat cerebral cortex in a model of chronic mild stress depression. PLoS ONE, 2018, 13, e0192329.	2.5	11
1002	International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. Pharmacological Reviews, 2018, 70, 475-504.	16.0	42
1003	Cortical thickness in major depressive disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 287-302.	4.8	113
1004	Sleep Disturbance in Bipolar Disorder: Neuroglia and Circadian Rhythms. Frontiers in Psychiatry, 2019, 10, 501.	2.6	41
1005	Biological Psychiatry and Psychopharmacology. , 2019, , 397-458.		0
1006	Cortical thickening in remitters compared to non-remitters with major depressive disorder following 8-week antidepressant treatment. Acta Psychiatrica Scandinavica, 2019, 140, 217-226.	4.5	14
1007	Cortical thickness following electroconvulsive therapy in patients with depression: a longitudinal MRI study. Acta Psychiatrica Scandinavica, 2019, 140, 205-216.	4.5	25
1008	<p></p>A single-nucleotide polymorphism influences brain morphology in drug-naïve patients with major depressive disorder</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2425-2432.	2.2	9
1009	<p></p>Impaired cognition in geriatric patients with relation to earlier life mood disorder and traumatic brain injury: a hypothesis</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2101-2104.	2.2	1
1010	Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists. Korean Journal of Physiology and Pharmacology, 2019, 23, 427.	1.2	10
1011	High urea induces depression and LTP impairment through mTOR signalling suppression caused by carbamylation. EBioMedicine, 2019, 48, 478-490.	6.1	28
1012	Neuroglia in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2019, , .	1.6	18
1013	Neurite atrophy in dorsal hippocampus of rat indicates incomplete recovery of chronic mild stress induced depression. NMR in Biomedicine, 2019, 32, e4057.	2.8	13

#	ARTICLE	IF	CITATIONS
1014	Ketamine normalizes binge drinking-induced defects in glutamatergic synaptic transmission and ethanol drinking behavior in female but not male mice. <i>Neuropharmacology</i> , 2019, 149, 35-44.	4.1	25
1015	Pathophysiology of Depression. , 2019, , 89-109.		0
1016	Electroencephalography-Based Diagnosis of Depression. , 2019, , 171-203.		1
1017	The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109668.	4.8	58
1018	Astrocyte, a Promising Target for Mood Disorder Interventions. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 136.	2.9	83
1019	Therapeutic Potential of Exogenous Ketone Supplement Induced Ketosis in the Treatment of Psychiatric Disorders: Review of Current Literature. <i>Frontiers in Psychiatry</i> , 2019, 10, 363.	2.6	44
1020	Neurobiologic properties of mood disorders may have an impact on epilepsy: Should this motivate neurologists to screen for this psychiatric comorbidity in these patients?. <i>Epilepsy and Behavior</i> , 2019, 98, 298-301.	1.7	13
1021	Isoflurane produces antidepressant effects inducing BDNF-TrkB signaling in CUMS mice. <i>Psychopharmacology</i> , 2019, 236, 3301-3315.	3.1	30
1022	Differential effects of unipolar versus bipolar depression on episodic memory updating. <i>Neurobiology of Learning and Memory</i> , 2019, 161, 158-168.	1.9	1
1023	Transmission electron microscopies for food quality evaluation. , 2019, , 763-792.		0
1024	Epilepsy and mood disorders. , 2019, , 299-314.		3
1025	An Integrated Model of Slow-Wave Activity and Neuroplasticity Impairments in Major Depressive Disorder. <i>Current Psychiatry Reports</i> , 2019, 21, 30.	4.5	14
1026	Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 634.	11.0	74
1027	Early-Life Adversity, but Not Suicide, Is Associated With Less Prefrontal Cortex Gray Matter in Adulthood. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 349-357.	2.1	27
1028	Regionally selective knockdown of astroglial glutamate transporters in infralimbic cortex induces a depressive phenotype in mice. <i>Glia</i> , 2019, 67, 1122-1137.	4.9	36
1029	Developments in depression in epilepsy: screening, diagnosis, and treatment. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 269-276.	2.8	15
1030	Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens. , 2019, , .		0
1031	Suicide and suicide risk. <i>Nature Reviews Disease Primers</i> , 2019, 5, 74.	30.5	450

#	ARTICLE	IF	CITATIONS
1032	Neurotrophic and Antidepressant Actions of Brain-Derived Neurotrophic Factor Require Vascular Endothelial Growth Factor. <i>Biological Psychiatry</i> , 2019, 86, 143-152.	1.3	73
1033	Homeostatic cAMP regulation by the RGS7 complex controls depression-related behaviors. <i>Neuropsychopharmacology</i> , 2019, 44, 642-653.	5.4	20
1034	Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets. <i>British Journal of Pharmacology</i> , 2019, 176, 3558-3584.	5.4	17
1035	Role of Neuronal VEGF Signaling in the Prefrontal Cortex in the Rapid Antidepressant Effects of Ketamine. <i>American Journal of Psychiatry</i> , 2019, 176, 388-400.	7.2	77
1036	Astrocytes. <i>Methods in Molecular Biology</i> , 2019, , .	0.9	1
1037	Glial Pathology in Major Depressive Disorder: An Approach to Investigate the Coverage of Blood Vessels by Astrocyte Endfeet in Human Postmortem Brain. <i>Methods in Molecular Biology</i> , 2019, 1938, 247-254.	0.9	7
1038	Examining the Coverage of Blood Vessels by Astrocyte Endfeet in an Animal Model of Major Depressive Disorder. <i>Methods in Molecular Biology</i> , 2019, 1938, 255-263.	0.9	3
1039	Aberrant brain regional homogeneity in first-episode drug-naïve patients with major depressive disorder: A voxel-wise meta-analysis. <i>Journal of Affective Disorders</i> , 2019, 245, 63-71.	4.1	29
1040	CAPON Is a Critical Protein in Synaptic Molecular Networks in the Prefrontal Cortex of Mood Disorder Patients and Contributes to Depression-Like Behavior in a Mouse Model. <i>Cerebral Cortex</i> , 2019, 29, 3752-3765.	2.9	12
1041	Oligodendrocyte gene expression is reduced by and influences effects of chronic social stress in mice. <i>Genes, Brain and Behavior</i> , 2019, 18, e12475.	2.2	46
1042	Distinctive Neuroanatomical Substrates for Depression in Bipolar Disorder versus Major Depressive Disorder. <i>Cerebral Cortex</i> , 2019, 29, 202-214.	2.9	39
1043	Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function. <i>Molecular Psychiatry</i> , 2019, 24, 916-927.	7.9	41
1044	A Neural Model of Empathic States in Attachment-Based Psychotherapy. <i>Computational Psychiatry</i> , 2020, 1, 132.	2.0	7
1045	Blood-brain barrier regulation in psychiatric disorders. <i>Neuroscience Letters</i> , 2020, 726, 133664.	2.1	178
1046	Decisional Capacity and Personality Disorders: Substantially Unable or Substantially Unwilling?. <i>Journal of Forensic Sciences</i> , 2020, 65, 655-660.	1.6	2
1047	Neuroprotective roles of neurotrophic factors in depression. , 2020, , 125-144.		3
1048	Identifying microbial life in rocks: Insights from population morphometry. <i>Geobiology</i> , 2020, 18, 282-305.	2.4	12
1049	Antidepressant-like effects of Î²-caryophyllene on restraint plus stress-induced depression. <i>Behavioural Brain Research</i> , 2020, 380, 112439.	2.2	40

#	ARTICLE	IF	CITATIONS
1050	The hypothalamic-pituitary-adrenal axis as a substrate for stress resilience: Interactions with the circadian clock. <i>Frontiers in Neuroendocrinology</i> , 2020, 56, 100819.	5.2	25
1051	Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 188, 172837.	2.9	113
1052	The correlation between adiponectin and FGF9 in depression disorder. <i>Brain Research</i> , 2020, 1729, 146596.	2.2	7
1053	Astrocyte control of glutamatergic activity: Downstream effects on serotonergic function and emotional behavior. <i>Neuropharmacology</i> , 2020, 166, 107914.	4.1	47
1054	Widespread Morphometric Abnormalities in Major Depression. <i>Neuroimaging Clinics of North America</i> , 2020, 30, 85-95.	1.0	4
1055	Sex differences in the transcription of glutamate transporters in major depression and suicide.. <i>Journal of Affective Disorders</i> , 2020, 277, 244-252.	4.1	5
1056	iTRAQ-based proteomics implies inflammasome pathway activation in the prefrontal cortex of CSDS mice may influence resilience and susceptibility. <i>Life Sciences</i> , 2020, 262, 118501.	4.3	3
1057	Astrocytes-induced neuronal inhibition contributes to depressive-like behaviors during chronic stress. <i>Life Sciences</i> , 2020, 258, 118099.	4.3	12
1058	Small ncRNA binding protein, PIWI: A potential molecular bridge between blood brain barrier and neuropathological conditions. <i>Medical Hypotheses</i> , 2020, 138, 109609.	1.5	2
1059	Astroglia-specific contributions to the regulation of synapses, cognition and behaviour. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 118, 331-357.	6.1	70
1060	Integrative omics analysis identifies differential biological pathways that are associated with regional grey matter volume changes in major depressive disorder. <i>Psychological Medicine</i> , 2022, 52, 924-935.	4.5	6
1061	Regulation of cannabinoid CB1 and CB2 receptors, neuroprotective mTOR and pro-apoptotic JNK1/2 kinases in postmortem prefrontal cortex of subjects with major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 276, 626-635.	4.1	8
1062	The Memory-Modifying Potential of Optogenetics and the Need for Neuroethics. <i>NanoEthics</i> , 2020, 14, 207-225.	0.8	15
1063	Convergent molecular, cellular, and cortical neuroimaging signatures of major depressive disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25138-25149.	7.1	90
1064	Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. <i>Frontiers in Pharmacology</i> , 2020, 11, 1270.	3.5	43
1065	Mast Cells, Astrocytes, Arachidonic Acid: Do They Play a Role in Depression?. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 3455.	2.5	8
1067	Astrocytes in rapid ketamine antidepressant action. <i>Neuropharmacology</i> , 2020, 173, 108158.	4.1	25
1068	Exercise, brain plasticity, and depression. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 885-895.	3.9	71

#	ARTICLE	IF	CITATIONS
1069	GSK3 β : A Master Player in Depressive Disorder Pathogenesis and Treatment Responsiveness. <i>Cells</i> , 2020, 9, 727.	4.1	42
1070	Overlapping evidence of innate immune dysfunction in psychotic and affective disorders. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 2, 100038.	2.5	19
1071	Encoding, Consolidation, and Renormalization in Depression: Synaptic Homeostasis, Plasticity, and Sleep Integrate Rapid Antidepressant Effects. <i>Pharmacological Reviews</i> , 2020, 72, 439-465.	16.0	28
1072	Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 169.	3.7	35
1073	Retinoic acid and depressive disorders: Evidence and possible neurobiological mechanisms. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 112, 376-391.	6.1	20
1074	Adverse Effects of Circadian Disorganization on Mood and Molecular Rhythms in the Prefrontal Cortex of Mice. <i>Neuroscience</i> , 2020, 432, 44-54.	2.3	16
1075	Genetic and pharmacological inactivation of astroglial connexin 43 differentially influences the acute response of antidepressant and anxiolytic drugs. <i>Acta Physiologica</i> , 2020, 229, e13440.	3.8	24
1076	A preliminary study of resting brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination. <i>PLoS ONE</i> , 2020, 15, e0226486.	2.5	4
1077	Rapid effects of S-ketamine on the morphology of hippocampal astrocytes and BDNF serum levels in a sex-dependent manner. <i>European Neuropsychopharmacology</i> , 2020, 32, 94-103.	0.7	24
1078	Increased Cortical Thickness in Patients With Major Depressive Disorder Following Antidepressant Treatment. <i>Chronic Stress</i> , 2020, 4, 247054701989996.	3.4	15
1079	Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment. <i>Neuropsychopharmacology</i> , 2020, 45, 982-989.	5.4	37
1080	Impaired ATP Release from Brain Astrocytes May be a Cause of Major Depression. <i>Neuroscience Bulletin</i> , 2020, 36, 1281-1284.	2.9	22
1081	Stress-Induced Morphological, Cellular and Molecular Changes in the Brain—Lessons Learned from the Chronic Mild Stress Model of Depression. <i>Cells</i> , 2020, 9, 1026.	4.1	34
1082	Longitudinal effects of rTMS on neuroplasticity in chronic treatment-resistant depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 39-47.	3.2	24
1083	The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder. <i>International Journal of Clinical Practice</i> , 2021, 75, e13739.	1.7	16
1084	Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer's disease pathology at death. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 713-721.	2.7	10
1085	Stress and Its Impact on the Transcriptome. <i>Biological Psychiatry</i> , 2021, 90, 102-108.	1.3	15
1086	Perisynaptic astrocytes as a potential target for novel antidepressant drugs. <i>Journal of Pharmacological Sciences</i> , 2021, 145, 60-68.	2.5	13

#	ARTICLE	IF	CITATIONS
1087	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	11.0	136
1088	Neurobiology of resilience in depression: immune and vascular insights from human and animal studies. European Journal of Neuroscience, 2021, 53, 183-221.	2.6	68
1089	The dentate gyrus in depression. European Journal of Neuroscience, 2021, 53, 39-64.	2.6	22
1090	Astrocytic plasticity at the dorsal dentate gyrus on an animal model of recurrent depression. Neuroscience, 2021, 454, 94-104.	2.3	15
1091	Molecular pathology associated with altered synaptic transcriptome in the dorsolateral prefrontal cortex of depressed subjects. Translational Psychiatry, 2021, 11, 73.	4.8	16
1093	Brain Imaging and the Mechanisms of Antidepressant Action. , 2021, , 248-260.		0
1094	Brain Imaging of Reward Dysfunction in Unipolar and Bipolar Disorders. , 2021, , 39-48.		0
1095	Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder. , 2021, , 236-247.		0
1096	Magnetoencephalography Studies in Mood Disorders. , 2021, , 192-205.		0
1098	Functional Near-Infrared Spectroscopy Studies in Mood Disorders. , 2021, , 166-174.		0
1100	Neuroimaging Studies of Effects of Psychotherapy in Depression. , 2021, , 261-272.		0
1101	Neurotoxicity in Depression. , 2021, , 1-30.		0
1102	Neuroimaging Brain Inflammation in Mood Disorders. , 2021, , 121-134.		0
1103	An Overview of Machine Learning Applications in Mood Disorders. , 2021, , 206-218.		0
1104	Serotonergic neurons in the treatment of mood disorders: The dialogue with astrocytes. Progress in Brain Research, 2021, 259, 197-228.	1.4	3
1105	Electrophysiological Biomarkers for Mood Disorders. , 2021, , 175-191.		1
1106	Antidepressants: Pharmacology and Biochemistry. , 2021, , 1-26.		0
1107	Role of Astrocytes in Major Neuropsychiatric Disorders. Neurochemical Research, 2021, 46, 2715-2730.	3.3	24

#	ARTICLE	IF	CITATIONS
1108	Neuroanatomical Findings in Bipolar Disorder. , 2021, , 16-27.		0
1109	Imaging Glutamatergic and GABAergic Abnormalities in Mood Disorders. , 2021, , 105-120.		0
1110	Magnetic Resonance Spectroscopy Investigations of Bioenergy and Mitochondrial Function in Mood Disorders. , 2021, , 83-104.		0
1111	Brain Imaging Methods in Mood Disorders. , 2021, , 1-6.		0
1112	Effects of Lithium on Brain Structure in Bipolar Disorder. , 2021, , 219-235.		1
1113	Functional network alterations differently associated with suicidal ideas and acts in depressed patients: an indirect support to the transition model. Translational Psychiatry, 2021, 11, 100.	4.8	30
1114	The Association Between Antidepressant Effect of SSRIs and Astrocytes: Conceptual Overview and Meta-Analysis of the Literature. Neurochemical Research, 2021, 46, 2731-2745.	3.3	8
1115	Widespread Decrease of Cerebral Vimentin-Immunoreactive Astrocytes in Depressed Suicides. Frontiers in Psychiatry, 2021, 12, 640963.	2.6	24
1116	A systematic review of neuroimaging studies of depression in adults with epilepsy. Epilepsy and Behavior, 2021, 115, 107695.	1.7	13
1117	Abnormal Large-Scale Network Activation Present in Bipolar Mania and Bipolar Depression Under Resting State. Frontiers in Psychiatry, 2021, 12, 634299.	2.6	9
1119	Implication of cerebral astrocytes in major depression: A review of fine neuroanatomical evidence in humans. Glia, 2021, 69, 2077-2099.	4.9	54
1120	Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?. Frontiers in Neuroscience, 2021, 15, 657714.	2.8	13
1121	Quantitative proteomic analysis of cortex in the depressive-like behavior of rats induced by the simulated complex space environment. Journal of Proteomics, 2021, 237, 104144.	2.4	4
1122	Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43. International Journal of Molecular Sciences, 2021, 22, 5623.	4.1	16
1123	Subfield-specific effects of chronic mild unpredictable stress on hippocampal astrocytes. European Journal of Neuroscience, 2021, 54, 5730-5746.	2.6	16
1124	Reduced anterior cingulate cortex volume induced by chronic stress correlates with increased behavioral emotionality and decreased synaptic puncta density. Neuropharmacology, 2021, 190, 108562.	4.1	11
1125	Ketamine Alters Functional Plasticity of Astroglia: An Implication for Antidepressant Effect. Life, 2021, 11, 573.	2.4	7
1126	Reward Processing in Psychiatric Inpatients With Depression. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2023, 8, 731-740.	1.5	6

#	ARTICLE	IF	CITATIONS
1127	Functional Contribution of the Medial Prefrontal Circuitry in Major Depressive Disorder and Stress-Induced Depressive-Like Behaviors. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 699592.	2.0	35
1128	Altered acoustic startle, prepulse facilitation, and object recognition memory produced by corticosterone withdrawal in male rats. <i>Behavioural Brain Research</i> , 2021, 408, 113291.	2.2	3
1129	Protection of Beta Boswellic Acid against Streptozotocin-induced Alzheimer's Model by Reduction of Tau Phosphorylation Level and Enhancement of Reelin Expression. <i>Planta Medica</i> , 2022, 88, 367-379.	1.3	8
1130	Automated morphometric analysis with SMorph software reveals plasticity induced by antidepressant therapy in hippocampal astrocytes. <i>Journal of Cell Science</i> , 2021, 134, .	2.0	7
1131	Reduced Brain Gray Matter Volume in Patients With First-Episode Major Depressive Disorder: A Quantitative Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2021, 12, 671348.	2.6	28
1132	Chronic Stress Induces Sex-Specific Functional and Morphological Alterations in Corticoaccumbal and Corticostriatal Pathways. <i>Biological Psychiatry</i> , 2021, 90, 194-205.	1.3	25
1133	Orbito-frontal thinning together with a somatoform dissociation might be the fingerprint of PNES. <i>Epilepsy and Behavior</i> , 2021, 121, 108044.	1.7	9
1134	Disrupting phosphorylation of Tyr-1070 at GluN2B selectively produces resilience to depression-like behaviors. <i>Cell Reports</i> , 2021, 36, 109612.	6.4	6
1135	Association of electroconvulsive therapy-induced structural plasticity with clinical remission. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110286.	4.8	8
1136	Distinct Effects of Escitalopram and Vortioxetine on Astroglial L-Glutamate Release Associated with Connexin43. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10013.	4.1	12
1139	Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression. <i>Pharmacological Research</i> , 2021, 171, 105761.	7.1	31
1140	Brain glycogen metabolism: A possible link between sleep disturbances, headache and depression. <i>Sleep Medicine Reviews</i> , 2021, 59, 101449.	8.5	20
1141	Isotretinoin and neuropsychiatric side effects: Continued vigilance is needed. <i>Journal of Affective Disorders Reports</i> , 2021, 6, 100230.	1.7	12
1142	Neuroimaging Biomarkers in Pediatric Mood Disorders. , 2021, , 28-38.		0
1143	Neuroanatomical Findings in Unipolar Depression and the Role of the Hippocampus. , 2021, , 7-15.		0
1144	Volumetric Deficit Within the Fronto-Limbic-Striatal Circuit in First-Episode Drug Naïve Patients With Major Depression Disorder. <i>Frontiers in Psychiatry</i> , 2020, 11, 600583.	2.6	12
1145	Functional Connectome in Bipolar Disorder. , 2021, , 59-82.		0
1146	Resting-State Functional Connectivity in Unipolar Depression. , 2021, , 49-58.		0

#	ARTICLE	IF	CITATIONS
1147	Imaging Genetic and Epigenetic Markers in Mood Disorders. , 2021, , 135-150.		0
1148	fMRI Neurofeedback as Treatment for Depression. , 2021, , 151-165.		0
1149	A Measured Milestone in Schizophrenia Research. Archives of General Psychiatry, 2000, 57, 74.	12.3	6
1150	Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety, 2000, 12, 2-19.	4.1	510
1154	Imaging the Neural Systems for Motivated Behavior and Their Dysfunction in Neuropsychiatric Illness. , 2006, , 763-810.		11
1155	Role of Neurotoxicity in Depression. , 2014, , 1567-1593.		1
1156	Quantitative Cytoarchitectonic Findings in Postmortem Brain Tissue from Mood Disorder Patients. Neurobiological Foundation of Aberrant Behaviors, 2002, , 291-324.	0.2	1
1157	Methodological and Stereological Considerations in Postmortem Psychiatric Brain Research. Neurobiological Foundation of Aberrant Behaviors, 2002, , 21-35.	0.2	3
1158	Glial Pathology in Major Psychiatric Disorders. Neurobiological Foundation of Aberrant Behaviors, 2002, , 49-73.	0.2	12
1159	Summary of Prefrontal Molecular Abnormalities in the Stanley Foundation Neuropathology Consortium. Neurobiological Foundation of Aberrant Behaviors, 2002, , 105-137.	0.2	2
1160	Pathology in Astroglia, Glutamate, and GABA in Major Depressive Disorder: Evidence from Studies of Human Postmortem Tissue. , 2014, , 245-264.		3
1161	Antidepressant Treatment of Geriatric Depression. , 2011, , 125-183.		3
1162	Neuroplasticity – A New Approach to the Pathophysiology of Depression. , 2011, , 1-12.		4
1163	Cellular Plasticity and the Pathophysiology of Depression. , 2011, , 41-55.		3
1164	Depressive Disorders: Prevalence, Costs, and Theories. , 2016, , 1-41.		3
1165	Neuroimaging Studies of Bipolar Depression: Therapeutic Implications. Milestones in Drug Therapy, 2016, , 137-181.	0.1	2
1166	Depressive Syndromes. , 2018, , 219-272.		1
1167	Neurotransmitter. , 2002, , 9-28.		4

#	ARTICLE	IF	CITATIONS
1168	Psychopharmakotherapie â€“ pharmakologische Grundlagen. , 2017, , 749-793.		2
1169	The Pathology of Synapses in Brain Networks Implicated in Depression. , 2013, , 107-132.		1
1170	General Pathophysiology of Astroglia. Advances in Experimental Medicine and Biology, 2019, 1175, 149-179.	1.6	43
1171	Subthreshold depression may exist on a spectrum with major depressive disorder: Evidence from gray matter volume and morphological brain network. Journal of Affective Disorders, 2020, 266, 243-251.	4.1	15
1172	Sleep and slow-wave activity in depressed adolescent boys: a preliminary study. Sleep Medicine, 2017, 38, 24-30.	1.6	15
1174	Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatrica Scandinavica, 2001, 104, 380-386.	4.5	128
1175	Synaptic plasticity and mood disorders. , 0, .		6
1176	Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. , 0, .		1
1177	The role of the ventral prefrontal cortex in mood disorders. , 2006, , 545-578.		3
1181	Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. Australian and New Zealand Journal of Psychiatry, 2006, 40, 725-741.	2.3	12
1182	GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. Journal of Clinical Investigation, 2016, 126, 2482-2494.	8.2	124
1183	Temporal Dissociation Between Lithium-Induced Changes in Frontal Lobe <i>m</i> -Inositol and Clinical Response in Manic-Depressive Illness. American Journal of Psychiatry, 1999, 156, 1902-1908.	7.2	164
1184	Executive Control Function: A Review of Its Promise and Challenges for Clinical Research. A Report From the Committee on Research of the American Neuropsychiatric Association. Journal of Neuropsychiatry and Clinical Neurosciences, 2002, 14, 377-405.	1.8	352
1185	Contribution of Pharmacology to Development of Monoaminergic Hypotheses of Depression. , 2011, , 152-175.		2
1186	Fear Extinction as a Model for Synaptic Plasticity in Major Depressive Disorder. PLoS ONE, 2014, 9, e115280.	2.5	42
1187	Increased cellular turnover in response to fluoxetine in neuronal precursors derived from human embryonic stem cells. International Journal of Developmental Biology, 2010, 54, 707-715.	0.6	14
1188	Adult neuroplasticity: A new â€œcureâ€•for major depression?. Journal of Psychiatry and Neuroscience, 2019, 44, 147-150.	2.4	22
1189	Transmembrane Prolyl 4-Hydroxylase is a Novel Regulator of Calcium Signaling in Astrocytes. ENeuro, 2021, 8, ENEURO.0253-20.2020.	1.9	10

#	ARTICLE	IF	CITATIONS
1191	Targeting Gap Junctions: New Insights into the Treatment of Major Depressive Disorder. <i>Current Medicinal Chemistry</i> , 2019, 26, 3775-3791.	2.4	13
1192	Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits. <i>Current Drug Targets</i> , 2013, 14, 1329-1335.	2.1	19
1193	Serum S100B Represents a New Biomarker for Mood Disorders. <i>Current Drug Targets</i> , 2013, 14, 1237-1248.	2.1	91
1194	Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue. <i>Current Drug Targets</i> , 2013, 14, 1225-1236.	2.1	481
1195	The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs. <i>Current Drug Targets</i> , 2013, 14, 1277-1294.	2.1	42
1196	Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine. <i>Current Neuropharmacology</i> , 2017, 15, 11-20.	2.9	118
1197	Pathophysiology of Depression and Novel Sources of Phytochemicals for its Treatment – A Systematic Review. <i>Acta Medica Bulgarica</i> , 2020, 47, 69-74.	0.1	3
1198	Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders. <i>Dialogues in Clinical Neuroscience</i> , 2002, 4, 73-92.	3.7	12
1199	Gonadal steroids, brain, and behavior: role of context. <i>Dialogues in Clinical Neuroscience</i> , 2002, 4, 123-137.	3.7	27
1200	Structural plasticity of the adult brain: how animal models help us understand brain changes in depression and systemic disorders related to depression. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 119-133.	3.7	34
1201	Cellular abnormalities in depression: evidence from postmortem brain tissue. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 185-197.	3.7	47
1202	Cellular plasticity and resilience and the pathophysiology of severe mood disorders. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 217-225.	3.7	9
1203	Regulation of cellular plasticity and resilience by mood stabilizers: the role of AMPA receptor trafficking. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 143-155.	3.7	12
1204	Neural plasticity: consequences of stress and actions of antidepressant treatment. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 157-169.	3.7	68
1205	Neuroplasticity in mood disorders. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 199-216.	3.7	44
1206	Changes in the immune system in depression and dementia: causal or coincidental effects?. <i>Dialogues in Clinical Neuroscience</i> , 2006, 8, 163-174.	3.7	41
1207	Cellular and molecular mechanisms in the long-term action of antidepressants.. <i>Dialogues in Clinical Neuroscience</i> , 2008, 10, 385-400.	3.7	128
1208	Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 239-255.	3.7	165

#	ARTICLE	IF	CITATIONS
1209	Stem cell approaches in psychiatry--challenges and opportunities. Dialogues in Clinical Neuroscience, 2009, 11, 397-404.	3.7	2
1210	Disorders of memory and plasticity in psychiatric disease. Dialogues in Clinical Neuroscience, 2013, 15, 455-463.	3.7	72
1211	Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues in Clinical Neuroscience, 2014, 16, 11-27.	3.7	195
1212	Increased DNA methylation in the suicide brain. Dialogues in Clinical Neuroscience, 2014, 16, 430-438.	3.7	74
1213	Astroglial Connexin43 as a Potential Target for a Mood Stabiliser. International Journal of Molecular Sciences, 2021, 22, 339.	4.1	25
1214	Antidepressant Activity of Alcoholic Extract of the Fruits of <i>Osmanthus fragrans</i> Lour in Mice. Research Journal of Medicinal Plant, 2015, 9, 187-193.	0.3	3
1215	Effects of glucocorticoids in depression: Role of astrocytes. AIMS Neuroscience, 2018, 5, 200-210.	2.3	5
1216	Pain and the Brain: Diabetic Neuropathic Pain. Journal of Clinical Psychiatry, 2008, 69, e22.	2.2	12
1217	Biological Vulnerabilities to the Development of Psychopathology. , 2005, , 75-103.		2
1218	The Biological Effects of Psychotherapy in Major Depressive Disorders: A Review of Neuroimaging Studies. Psychology, 2012, 03, 857-863.	0.5	6
1219	Stress Changes the Spatial Arrangement of Neurons and Glial Cells of Medial Prefrontal Cortex and Sertraline and Curcumin Prevent It. Psychiatry Investigation, 2015, 12, 73.	1.6	15
1220	Layer 2/3 pyramidal cells in the medial prefrontal cortex moderate stress induced depressive behaviors. ELife, 2015, 4, .	6.0	63
1221	Neuroplasticity and the Biological Role of Brain Derived Neurotrophic Factor in the Pathophysiology and Management of Depression. Cureus, 2020, 12, e11396.	0.5	9
1222	Chronic Fluoxetine Administration during Different Postnatal Development Stages Leads to Stage Dependent Changes of Glial Fibrillary Acidic Protein Expression in Rat Brain. British Journal of Medicine and Medical Research, 2012, 2, 292-312.	0.2	1
1223	Psychedelics and Other Psychoplastogens for Treating Mental Illness. Frontiers in Psychiatry, 2021, 12, 727117.	2.6	70
1224	Molecular characterization of depression trait and state. Molecular Psychiatry, 2022, 27, 1083-1094.	7.9	22
1225	Functional near-infrared spectroscopy during the verbal fluency task of English-Speaking adults with mood disorders: A preliminary study. Journal of Clinical Neuroscience, 2021, 94, 94-101.	1.5	14
1226	Macroanatomical Findings in Post-Mortem Brain Tissue. Neurobiological Foundation of Aberrant Behaviors, 2002, , 277-289.	0.2	0

#	ARTICLE	IF	CITATIONS
1227	Non-Monoaminergic Transmitters, Glia Cell Markers, Cell Adhesion Molecules and Synaptic Proteins in Postmortem Brain Tissue. Neurobiological Foundation of Aberrant Behaviors, 2002, , 387-394.	0.2	0
1228	Neurobiologische Grundlagen. , 2002, , 1-77.		0
1229	Monoamine Receptors in Postmortem Brain: Do Postmortem Brain Studies Cloud or Clarify our Understanding of the Affective Disorders?. Neurobiological Foundation of Aberrant Behaviors, 2002, , 363-385.	0.2	1
1230	Regulation of Neural Stem Cells in the Adult Mammalian Brain. , 2003, , 219-256.		0
1231	Antidepressant Treatment of Geriatric Depression. , 2004, , 119-163.		0
1232	Do degenerative changes operate across diagnostic boundaries? The case for glucocorticoid involvement in major psychiatric disorders. , 2004, , 111-120.		0
1233	Psychopharmakotherapie – Pharmakologische Grundlagen. , 2008, , 583-623.		0
1235	Alteraciones de las concentraciones de factor neurotrófico derivado de la línea de células gliales (GDNF) en el cerebro de pacientes con trastorno depresivo: Estudio comparativo post mortem.. European Psychiatry (Ed Española), 2008, 15, 398-406.	0.0	0
1236	Neurobiologic Aspects of Late-Life Mood Disorders. Medical Psychiatry, 2008, , 133-150.	0.2	0
1237	Diabetes and Depression. , 2009, , 343-363.		0
1238	Neuroimaging studies of bipolar depression: therapeutic implications. , 2009, , 117-144.		0
1239	Neuroimaging and Electrophysiology Studies in Major Depressive Disorder. Medical Psychiatry, 2009, , 150-165.	0.2	0
1240	Entzündliche Veränderungen als gemeinsame Pathogenese affektiver und schizophrener Erkrankungen. , 2010, , 59-91.		0
1241	Neuroprotective Agents in Mood Disorders: Pathophysiological and Therapeutic Implications. , 2010, , 417-449.		0
1242	Psychopharmakotherapie: pharmakologische Grundlagen. , 2011, , 683-729.		0
1243	The HPA axis and GABA-Glutamate Systems as Potential Antidepressant Targets in Prostate Cancer. The Open Prostate Cancer Journal, 2011, 4, 1-5.	0.4	0
1244	Interaction Between Inflammatory State and Neurochemical Changes in Major Psychiatric Disorders. , 0, , .		0
1245	Psychiatric Disorders - Worldwide Advances. , 2011, , .		1

#	ARTICLE	IF	CITATIONS
1246	14. Plasticity of cAMP response element binding protein and potential role of cAMP response element binding protein in the regulation of gene expression. , 2012, , 85-89.		0
1247	Neuroimaging Studies of Bipolar and Unipolar Depression. , 2012, , 125-146.		1
1248	Peri-ictal Dysphoria and the Other Pleomorphic Manifestations of Depression in Epilepsy. , 2012, , 297-307.		0
1250	Psychiatric Disorders. , 2013, , .		0
1251	Association of depression with epilepsy. IOSR Journal of Dental and Medical Sciences, 2014, 13, 52-55.	0.0	0
1252	Synaptic Stress, Changes in Glutamate Transmission and Circuitry, and Psychopathology. , 2014, , 33-52.		1
1254	Modafinil Enhances Two-Year Outcome from Monoamine Oxidase Inhibitor Therapy in 3 Patients with Treatment-Resistant Depression. Advances in Pharmacoeconomics & Drug Safety, 2015, 04, .	0.1	0
1255	Neuronale Substrate der Depression und Implikationen für die Psychotherapie. , 2016, , 411-424.		0
1256	Exercise as an Adjunct to Treating Depression. , 2015, , 307-332.		0
1258	Anti-Inflammatory and Immune-Modulatory Therapeutic Approaches in Major Depression. , 2016, , 115-141.		0
1259	The Brain Mechanism of Depression: Evidence from the Brain Midline Areas. Advances in Psychology, 2016, 06, 1166-1173.	0.1	1
1260	Major Depressive Disorder and Heroin-dependent Patients Share Decreased Frontal Gray Matter Volumes: A Voxel-Based Morphometry Study. International Journal of Emergency Mental Health, 2016, 18, .	0.3	1
1261	Neuroprotective effects of agmatine and hippocampal neuron loss in the depression. Biomedical Research and Reviews, 2018, 2, .	0.1	0
1263	Neurocognitive Mechanisms for Detecting Early Phase of Depressive Disorder. Advances in Medical Technologies and Clinical Practice Book Series, 2019, , 165-198.	0.3	0
1264	GABAergic transmission and modulation of anxiety: A review on molecular aspects. Brazilian Journal of Biological Sciences, 2019, 6, 9-16.	0.2	2
1265	Effects of Chronic Stress on Emotion and Neural Mechanism: Focus on Sex Difference. Advances in Psychology, 2019, 09, 1803-1815.	0.1	0
1267	Evaluation of Potentiation Effect of Omega-3 Fatty Acid on the Antidepressant Efficacy of Escitalopram in Albino Rats. Biomedical and Pharmacology Journal, 2019, 12, 1471-1480.	0.5	0
1268	Posttraumatic Hypopituitarism: Neuroendocrine Dysfunction and Treatment. , 2020, , 197-214.		0

#	ARTICLE	IF	CITATIONS
1269	Comorbid Psychiatric Illnesses. , 2020, , 139-178.		1
1273	Targeting the Neuronal Activity of Prefrontal Cortex: New Directions for the Therapy of Depression. Current Neuropharmacology, 2020, 18, 332-346.	2.9	8
1274	Volumetric brain imaging studies in the elderly with mood disorders. Current Psychiatry Reports, 1996, 8, 18-24.	4.5	0
1276	Psychiatric Disorders. , 2005, , 453-464.		0
1277	Neuroprotektive Effekte der Antidepressiva und Mood Stabilizer. , 2005, , 543-550.		0
1278	Status of neurosurgery for mental disorder in Scotland: Selective literature review and overview of current clinical activity. British Journal of Psychiatry, 2003, 182, 404-411.	2.8	0
1279	Status of neurosurgery for mental disorder in Scotland: Selective literature review and overview of current clinical activity. British Journal of Psychiatry, 2003, 182, 404-411.	2.8	0
1280	Zukunftsstrategien für die Entdeckung neuer Antidepressiva. , 2008, , 125-145.		1
1284	Neuroprotective effects of antidepressant and mood stabilizing drugs. Journal of Psychiatry and Neuroscience, 2002, 27, 8-9.	2.4	35
1285	Implications of adult hippocampal neurogenesis in antidepressant action. Journal of Psychiatry and Neuroscience, 2004, 29, 196-205.	2.4	137
1286	The role of the hippocampus in the pathophysiology of major depression. Journal of Psychiatry and Neuroscience, 2004, 29, 417-26.	2.4	529
1287	The underlying neurobiology of bipolar disorder. World Psychiatry, 2003, 2, 136-46.	10.4	97
1288	Enhanced rostral anterior cingulate cortex activation during cognitive control is related to orbitofrontal volume reduction in unipolar depression. Journal of Psychiatry and Neuroscience, 2008, 33, 199-208.	2.4	77
1289	Alcohol dependence-related increase of glial cell density in the anterior cingulate cortex of suicide completers. Journal of Psychiatry and Neuroscience, 2009, 34, 281-8.	2.4	21
1299	The Beginning of Psychosis: Psychological and Environmental Factors That Lead To Psychosis and Their Relationship to Biological Factors. International Journal of Medical Science and Clinical Research Studies, 2021, 01, .	0.0	0
1300	Morphological Features of Astrocytes in Health and Neuropsychiatric Disorders. Advances in Neurobiology, 2021, 26, 75-92.	1.8	3
1302	Rapid and Sustained Restoration of Astrocytic Functions by Ketamine in Depression Model Mice. SSRN Electronic Journal, 0, , .	0.4	0
1303	Ketamine Action on Astrocytes Provides New Insights into Rapid Antidepressant Mechanisms. Advances in Neurobiology, 2021, 26, 349-365.	1.8	9

#	ARTICLE	IF	CITATIONS
1304	Involvement of Incomplete Hippocampal Inversion in Intractable Epilepsy: Evidence from Neuropsychological Studies. <i>Neurology India</i> , 2021, 69, 842.	0.4	2
1305	Pathogenesis of seizures and epilepsy after stroke. <i>Acta Epileptologica</i> , 2022, 4, .	0.9	11
1306	Astrocytes in Neuropsychiatric Disorders: A Review of Postmortem Evidence. <i>Advances in Neurobiology</i> , 2021, 26, 153-172.	1.8	7
1307	Bidirectional Relations Among Depression, Migraine, and Epilepsy: Do They Have an Impact on Their Response to Treatment?. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 1.	1.7	0
1308	S-Ketamine Exerts Antidepressant Effects by Regulating Rac1 GTPase Mediated Synaptic Plasticity in the Hippocampus of Stressed Rats. <i>Cellular and Molecular Neurobiology</i> , 2023, 43, 299-314.	3.3	11
1309	Beyond New Neurons in the Adult Hippocampus: Imipramine Acts as a Pro-Astroglial Factor and Rescues Cognitive Impairments Induced by Stress Exposure. <i>Cells</i> , 2022, 11, 390.	4.1	9
1310	Targeting epigenetics as future treatments of trauma- and stress-or-related disorders. <i>Epidrugs and epinutraceuticals</i> . , 2022, , 317-392.		1
1311	Decreased number and increased activation state of astrocytes in gray and white matter of the prefrontal cortex in autism. <i>Cerebral Cortex</i> , 2022, 32, 4902-4912.	2.9	11
1312	The ATP Level in the Medial Prefrontal Cortex Regulates Depressive-like Behavior via the Medial Prefrontal Cortex-Lateral Habenula Pathway. <i>Biological Psychiatry</i> , 2022, 92, 179-192.	1.3	37
1313	A Review of Ocular Complications Associated with Medications Used for Anxiety, Depression, and Stress. <i>Clinical Optometry</i> , 2022, Volume 14, 13-25.	1.2	6
1314	LaminaRGeneVis: A Tool to Visualize Gene Expression Across the Laminar Architecture of the Human Neocortex. <i>Frontiers in Neuroinformatics</i> , 2022, 16, 753770.	2.5	0
1315	Aberrant Inter-hemispheric Connectivity in Patients With Recurrent Major Depressive Disorder: A Multimodal MRI Study. <i>Frontiers in Neurology</i> , 2022, 13, 852330.	2.4	4
1316	Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 673-690.	2.4	17
1317	Shared and Unshared Feature Extraction in Major Depression During Music Listening Using Constrained Tensor Factorization. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 799288.	2.0	0
1318	Differences in electric field strength between clinical and non-clinical populations induced by prefrontal tDCS: A cross-diagnostic, individual MRI-based modeling study. <i>NeuroImage: Clinical</i> , 2022, 34, 103011.	2.7	13
1320	Molecular Pathogenesis for Schizophrenia and Major Depression. , 2008, , 511-530.		0
1322	Biological Treatments of Mood Disorders. , 0, , 143-166.		0
1323	Introductory and Basic Aspects. , 0, , 2-50.		0

#	ARTICLE	IF	CITATIONS
1325	P2X2 receptors in pyramidal neurons are critical for regulating vulnerability to chronic stress. <i>Theranostics</i> , 2022, 12, 3703-3718.	10.0	6
1326	Ultrasound Stimulation of Prefrontal Cortex Improves Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice. <i>Frontiers in Psychiatry</i> , 2022, 13, 864481.	2.6	16
1327	Synaptic Mechanisms Regulating Mood State Transitions in Depression. <i>Annual Review of Neuroscience</i> , 2022, 45, 581-601.	10.7	30
1328	Sparse sliced inverse regression for high dimensional data analysis. <i>BMC Bioinformatics</i> , 2022, 23, 168.	2.6	0
1329	Astrocyte regulation of synaptic signaling in psychiatric disorders. <i>Neuropsychopharmacology</i> , 2023, 48, 21-36.	5.4	27
1331	Differences in Electric Field Strength between Clinical and Non-Clinical Populations Induced by Prefrontal Tdcs: A Cross-Diagnostic, Individual MRI Based Modeling Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1332	Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression. <i>Journal of Neuroinflammation</i> , 2022, 19, .	7.2	119
1333	Transcriptome Profiling of the Dorsomedial Prefrontal Cortex in Suicide Victims. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7067.	4.1	4
1334	Antidepressant chronotherapeutics normalizes prefrontal 1H-MRS glutamate in bipolar depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 119, 110606.	4.8	4
1335	Personalizing repetitive transcranial magnetic stimulation for precision depression treatment based on functional brain network controllability and optimal control analysis. <i>NeuroImage</i> , 2022, 260, 119465.	4.2	7
1336	Task-Related Neural Activation Abnormalities in Patients with Remitted Major Depressive Disorder: A Coordinate-Based Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1337	Predicting Antidepressant Effects of Ketamine: the Role of the Pregenual Anterior Cingulate Cortex as a Multimodal Neuroimaging Biomarker. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 1003-1013.	2.1	3
1338	Neurochemical Signaling in Depression: Impact of Target-Based Pharmaceuticals. <i>Current Drug Therapy</i> , 2022, 17, .	0.3	0
1339	Post-Mortem Analysis of Neuropathological Changes in Human Tinnitus. <i>Brain Sciences</i> , 2022, 12, 1024.	2.3	2
1340	A new path to mental disorders: Through gap junction channels and hemichannels. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 142, 104877.	6.1	1
1341	Gray Matter Volume Reduction in Orbitofrontal Cortex Correlated with Plasma Glial Cell-Derived Neurotrophic Factor (GDNF) Levels within Major Depressive Disorder. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1342	Root-Cause Analysis of Activation Cascade Differences in Brain Networks. <i>Lecture Notes in Computer Science</i> , 2022, , 86-98.	1.3	0
1343	More than a marker: potential pathogenic functions of MAP2. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	2.9	26

#	ARTICLE	IF	CITATIONS
1344	Multiscale neural gradients reflect transdiagnostic effects of major psychiatric conditions on cortical morphology. <i>Communications Biology</i> , 2022, 5, .	4.4	23
1345	Layer III pyramidal cells in the prefrontal cortex reveal morphological changes in subjects with depression, schizophrenia, and suicide. <i>Translational Psychiatry</i> , 2022, 12, .	4.8	4
1346	Generalizability of treatment outcome prediction in major depressive disorder using structural MRI: A NeuroPharm study. <i>NeuroImage: Clinical</i> , 2022, 36, 103224.	2.7	6
1347	Targeting NMDA Receptors in Emotional Disorders: Their Role in Neuroprotection. <i>Brain Sciences</i> , 2022, 12, 1329.	2.3	7
1348	Evaluation of Prefrontal \hat{I}^3 -Aminobutyric Acid and Glutamate Levels in Individuals With Major Depressive Disorder Using Proton Magnetic Resonance Spectroscopy. <i>JAMA Psychiatry</i> , 2022, 79, 1209.	11.0	9
1349	Prenatal SAMe Treatment Induces Changes in Brain Monoamines and in the Expression of Genes Related to Monoamine Metabolism in a Mouse Model of Social Hierarchy and Depression, Probably via an Epigenetic Mechanism. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11898.	4.1	3
1350	Gene Enrichment Analysis of Astrocyte Subtypes in Psychiatric Disorders and Psychotropic Medication Datasets. <i>Cells</i> , 2022, 11, 3315.	4.1	2
1351	Task-related neural activation abnormalities in patients with remitted major depressive disorder: A coordinate-based meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 143, 104929.	6.1	1
1352	Antidepressants: Pharmacology and Biochemistry. , 2022, , 1109-1134.		0
1353	Transcranial alternating current stimulation ameliorates emotional attention through neural oscillations modulation. <i>Cognitive Neurodynamics</i> , 0, , .	4.0	2
1354	Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 26, 100554.	2.5	8
1355	Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine. <i>Neuropharmacology</i> , 2023, 224, 109335.	4.1	16
1357	A voxel-based meta-analysis comparing medication-naïve patients of major depression with treated longer-term ill cases. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, 144, 104991.	6.1	6
1358	NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research. <i>Neuropharmacology</i> , 2023, 225, 109378.	4.1	10
1359	Depression: magnetic resonance spectroscopy studies (review). <i>Translational Medicine</i> , 2022, 9, 20-32.	0.4	0
1360	Necroptotic kinases are involved in the reduction of depression-induced astrocytes and fluoxetine's inhibitory effects on necroptotic kinases. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	5
1361	Transcriptional substrates of brain structural and functional impairments in drug-naïve first-episode patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2023, 325, 522-533.	4.1	6
1362	Hyper-inflammation of astrocytes in patients of major depressive disorder: Evidence from serum astrocyte-derived extracellular vesicles. <i>Brain, Behavior, and Immunity</i> , 2023, 109, 51-62.	4.1	17

#	ARTICLE	IF	CITATIONS
1363	Gray matter volume reduction in orbitofrontal cortex correlated with plasma glial cell line-derived neurotrophic factor (GDNF) levels within major depressive disorder. <i>NeuroImage: Clinical</i> , 2023, 37, 103341.	2.7	1
1364	Inflammation, stress and depression: An exploration of ketamine's therapeutic profile. <i>Drug Discovery Today</i> , 2023, 28, 103518.	6.4	14
1365	Neurotoxicity in Depression. , 2022, , 2085-2114.		0
1366	13- <i>cis</i> -Retinoic Acid Affects Brain Perfusion and Function: In Vivo Study. <i>Molecular Imaging</i> , 2023, 2023, .	1.4	1
1367	Plausible Role of Stem Cell Types for Treating and Understanding the Pathophysiology of Depression. <i>Pharmaceutics</i> , 2023, 15, 814.	4.5	4
1368	Carotenoids: Role in Neurodegenerative Diseases Remediation. <i>Brain Sciences</i> , 2023, 13, 457.	2.3	2
1369	Role of <i>miR-124-3p</i> in regulatory mechanisms of <i>Gpm6a</i> expression in the hippocampus of chronically stressed rats. <i>Journal of Neurochemistry</i> , 0, , .	3.9	0
1370	Thrombospondin1 mimics rapidly relieve depression via Shank3 dependent uncoupling between dopamine D1 and D2 receptors. <i>IScience</i> , 2023, 26, 106488.	4.1	1
1371	Fraxetin attenuates disrupted behavioral and central neurochemical activity in a model of chronic unpredictable stress. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	5
1372	Potential Roles of m6A and FTO in Synaptic Connectivity and Major Depressive Disorder. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6220.	4.1	6
1374	A Review of Research on the Association between Neuron's Astrocyte Signaling Processes and Depressive Symptoms. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6985.	4.1	2
1375	Integrating genetics and transcriptomics to study major depressive disorder: a conceptual framework, bioinformatic approaches, and recent findings. <i>Translational Psychiatry</i> , 2023, 13, .	4.8	3
1376	Association of hospitalization with structural brain alterations in patients with affective disorders over nine years. <i>Translational Psychiatry</i> , 2023, 13, .	4.8	1
1377	Latroeggtxin-VI protects nerve cells and prevents depression by inhibiting NF- κ B signaling pathway activation and excessive inflammation. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
1378	Cell type specific transcriptomic differences in depression show similar patterns between males and females but implicate distinct cell types and genes. <i>Nature Communications</i> , 2023, 14, .	12.8	12
1380	Exploring the Heart's Mind Connection: Unraveling the Shared Pathways between Depression and Cardiovascular Diseases. <i>Biomedicines</i> , 2023, 11, 1903.	3.2	7
1381	Subtyping Brain Diseases from Imaging Data. <i>Neuromethods</i> , 2023, , 491-510.	0.3	1
1382	Chronic Stress, Depression, and Alzheimer's Disease: The Triangle of Oblivion. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 303-315.	1.6	1

